<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugSourcesOutput xmlns:ns2="local"><Sources><Source id="998480" type="PR">Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY and Establishment of an Oncology Collaboration with Otsuka</Source><Source id="979396" type="PR">Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb</Source><Source id="971181" type="PR">Lower dose SPRYCEL approved for patients with chronic phase CML</Source><Source id="955329" type="PR">Bristol-Myers Squibb Continues Excellent Financial Performance Led By Double-Digit Global Net Sales Growth and Strong Earnings Results</Source><Source id="927668" type="PR">Bristol-Myers Squibb Continues Strong Financial Performance Led by Double-Digit Global Sales Growth</Source><Source id="916528" type="PR">Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia</Source><Source id="899323" type="PR">Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company</Source><Source id="897699" type="PR">VioQuest Pharmaceuticals' Novel Akt Inhibitor VQD-002 is Synergistic with Various Cancer Therapies in Preclinical Studies</Source><Source id="872463" type="PR">Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007</Source><Source id="853256" type="PR">Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data</Source><Source id="849491" type="PR">FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML</Source><Source id="843696" type="PR">Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2007</Source><Source id="832823" type="PR">ChemGenex announces second publication demonstrating activity of ceflatonin in T315I-positive chronic myeloid leukemia (CML)</Source><Source id="816134" type="PR">Bristol-Myers Squibb Company Reports Financial Results for the Second Quarter and First Half of 2007</Source><Source id="787568" type="PR">Bristol-Myers Squibb Company Reports First Quarter 2007 Financial Results</Source><Source id="778846" type="PR">Health Canada approves SPRYCEL, a new treatment for chronic myeloid leukemia</Source><Source id="760273" type="PR">Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2006 and Announces EPS Guidance for 2007</Source><Source id="750066" type="PR">STUDY OF SPRYCEL(R) (DASATINIB) OR 800 MG OF GLEEVEC(R)* (IMATINIB MESYLATE) SHOWS PATIENTS TREATED WITH SPRYCEL ACHIEVED HIGH CYTOGENETIC RESPONSES AND PROLONGED PROGRESSION-FREE SURVIVAL</Source><Source id="750059" type="PR">STUDY SHOWS SPRYCEL(R) (DASATINIB) 100 MG ONCE A DAY PROVIDES RESPONSES SIMILAR TO THOSE IN PATIENTS TAKING APPROVED 70 MG TWICE A DAY DOSE, WITH REDUCED INCIDENCE OF SIDE EFFECTS</Source><Source id="749942" type="PR">ChemGenex Investigators Report Activity of Ceflatonin and Gleevec Combination Therapy in CML Patients Resistant to Gleevec Alone</Source><Source id="749859" type="PR">New Options to Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance</Source><Source id="744986" type="PR">SPRYCEL (Dasatinib) Approved in Europe - the First Significant Advance for Treatment-Resistant CML and Ph+ ALL Leukaemia Patients in Five Years</Source><Source id="742430" type="PR">Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice Presidents</Source><Source id="734869" type="PR">Bristol-Myers Squibb Company reports financial results for the third quarter and first nine months of 2006</Source><Source id="725445" type="PR">COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SEPTEMBER 2006 PLENARY MEETING MONTHLY REPORT</Source><Source id="692749" type="PR">Meeting highlights from the Committee for Medicinal Products for Human Use, 18-21 September 2006</Source><Source id="680484" type="PR">Bristol-Myers Squibb Company Reports Financial Results for the Second Quarter and First Half of 2006</Source><Source id="676525" type="PR">FDA Gives Rapid Approval for a New Treatment For a Rare Type of Leukemia</Source><Source id="676261" type="PR">FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications</Source><Source id="674218" type="PR">Data from a Randomised Phase II Study of Dasatinib or 800 mg/day Imatinib-Mesylate (Glivec(R)) Presented at the 11th Congress of the European Hematology Association</Source><Source id="674217" type="PR">Results From Phase II Studies of Dasatinib in Patients With Chronic Myeloid Leukaemia or Ph+ Acute Lymphocytic Leukaemia With Resistance or Intolerance to Imatinib</Source><Source id="671158" type="PR">Data From a Randomized Phase II Study of Dasatinib or 800 Mg/Day Imatinib- Mesylate (Gleevec(R)) Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology</Source><Source id="671113" type="PR">Bristol-Myers Squibb Issues Statement on Oncologic Drugs Advisory Committee Vote in Favor of Investigational Drug Dasatinib</Source><Source id="664260" type="PR">Bristol-Myers Squibb Company Reports First Quarter 2006 Financial Results</Source><Source id="654196" type="PR">FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib</Source><Source id="646807" type="PR">Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2005 and Announces EPS Guidance for 2006</Source><Source id="645104" type="PR">Committee for orphan medicinal products January 2006 meeting</Source><Source id="642881" type="PR">Bristol-Myers Squibb Submits New Drug Application for Dasatinib</Source><Source id="639980" type="PR">Bristol-Myers Squibb Updates the Investment Community on the Continued Execution of the Company's Strategy</Source><Source id="634918" type="PR">Committee for Orphan Medicinal Products</Source><Source id="631078" type="PR">Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2005, Reflecting Ongoing Investments in Strategy Aimed at Delivering Sustainable Growth</Source><Source id="614772" type="PR">Bristol-Myers Squibb Announces Financial Results for the Second Quarter and First Half of 2005, with Businesses on Plan, Led By Pharmaceutical Growth Drivers</Source><Source id="574472" type="PR">Phase I Study Results of Investigational Agent BMS-354825 in Patients With Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia Presented at the 46th Annual Meeting of the American Society of Hematology</Source><Source id="574468" type="PR">New Compound Discovered by Researchers Funded by The Leukemia &amp;amp; Lymphoma Society Proves Overwhelmingly Successful in Overcoming Resistance to Gleevec in Phase I Trial</Source><Source id="574460" type="PR">New Treatment for Patients with Imatinib-Resistant Leukemia</Source><Source id="2152629" type="PR">Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019</Source><Source id="2152386" type="PR">Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders</Source><Source id="2145406" type="PR">Bristol-Myers Squibb Reports First Quarter Financial Results</Source><Source id="2122615" type="PR">EMA - CHMP Minutes of the meeting on 10-13 December 2018</Source><Source id="2118545" type="PR">European Commission Approves Bristol-Myers Squibb's Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</Source><Source id="2113836" type="PR">Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results</Source><Source id="2109014" type="PR">First-in-human trial of senolytic drugs encouraging</Source><Source id="2107607" type="PR">Bristol-Myers Squibb's Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</Source><Source id="2104907" type="PR">Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</Source><Source id="2104899" type="PR">Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018</Source><Source id="2100207" type="PR">Bristol-Myers Squibb to Highlight New Data from Broad Oncology Portfolio at the 60th American Society of Hematology Annual Meeting</Source><Source id="2087123" type="PR">Bristol-Myers Squibb Reports Third Quarter Financial Results</Source><Source id="2067969" type="PR">U.S. Food and Drug Administration Accepts Bristol-Myers Squibb's Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</Source><Source id="2057579" type="PR">Bristol-Myers Squibb Reports Second Quarter Financial Results</Source><Source id="2051683" type="PR">European Commission Approves Expanded Indication for Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase</Source><Source id="2029648" type="PR">Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs</Source><Source id="2028694" type="PR">Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2018</Source><Source id="2028161" type="PR">Bristol-Myers Squibb Reports First Quarter Financial Results</Source><Source id="2011926" type="PR">PDCO monthly report of opinions on paediatric investigation plans and other activities</Source><Source id="2004201" type="PR">PDCO monthly report of opinions on paediatric investigation plans and other activities</Source><Source id="2002496" type="PR">Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results</Source><Source id="1998573" type="PR">PDCO monthly report of opinions on paediatric investigation plans and other activities 12-15 December 2017</Source><Source id="1992863" type="PR"> U.S. FDA Approves Pfizer's BOSULIF (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)</Source><Source id="1990167" type="PR">Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</Source><Source id="1981238" type="PR">U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase</Source><Source id="1974986" type="PR">Bristol-Myers Squibb Reports Third Quarter Financial Results </Source><Source id="1948753" type="PR">Bristol-Myers Squibb Reports Second Quarter Financial Results</Source><Source id="1943958" type="PR">U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Sprycel (dasatinib) in Children with Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia</Source><Source id="1934639" type="PR">Early, Durable Responses Seen with Sprycel (dasatinib) in First- and Second-Line Treatment of Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML)</Source><Source id="1929309" type="PR">European Medicines Agency Validates Application for Bristol-Myers Squibb's Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia</Source><Source id="1928599" type="PR">Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017</Source><Source id="1922226" type="PR">Bristol-Myers Squibb Reports First Quarter Financial Results</Source><Source id="1900080" type="PR">Consolidated Financial Results for the Fiscal Year Ended December 31, 2016 [IFRS]</Source><Source id="1897286" type="PR">Bristol-Myers Squibb Announces European Patent Office Decision on Sprycel</Source><Source id="1895599" type="PR">Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results</Source><Source id="1887852" type="PR">Imatinib Accord Launch</Source><Source id="1867406" type="PR">Bristol-Myers Squibb Reports Third Quarter Financial Results</Source><Source id="1795969" type="PR">Inhibikase Therapeutics, Inc. Receives FDA Clearance To Initiate Clinical Trials For Potential Disease-Modifying Therapies To Treat Parkinson's Disease</Source><Source id="1786925" type="PR">Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2016 </Source><Source id="1783948" type="PR">Bristol-Myers Squibb Reports Second Quarter Financial Results</Source><Source id="1761886" type="PR">Otsuka:  Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2016 [Japan GAAP]</Source><Source id="1757088" type="PR">Bristol-Myers Squibb Reports First Quarter Financial Results</Source><Source id="1750851" type="PR">Two Indian generics makers end battle to copy drugs amid patent debate</Source><Source id="1743911" type="PR">Using generic cancer drug could save many millions of dollars</Source><Source id="1734473" type="PR">Otsuka Consolidated Financial Results for the Fiscal Year Ended December 31, 2015</Source><Source id="1731161" type="PR">Sun Pharma launches Imatinib Mesylate in USA</Source><Source id="1730526" type="PR">Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results</Source><Source id="1725240" type="PR">Cancer drug shows promise for treating Duchenne muscular dystrophy</Source><Source id="1713269" type="PR">Otsuka:  Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2015 [Japan GAAP]</Source><Source id="1706902" type="PR">Bristol-Myers Squibb Reports Third Quarter Financial Results</Source><Source id="1686216" type="PR">FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase</Source><Source id="1684580" type="PR">Otsuka Business Results for 2Q (August 7, 2015)</Source><Source id="1680444" type="PR">BDR Pharma seeks licence for Bristol Myers drug</Source><Source id="1680012" type="PR">Bristol-Myers Squibb Reports Second Quarter Financial Results</Source><Source id="1659255" type="PR">Otsuka Holdings Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2015 [Japan GAAP]</Source><Source id="1654807" type="PR">Bristol-Myers Squibb Reports First Quarter Financial Results</Source><Source id="1639974" type="PR">Mayo Clinic and Collaborators Find New Class of Drugs that Reduces Aging in Mice</Source><Source id="1637546" type="PR">Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area</Source><Source id="1633667" type="PR">Consolidated Financial Results for the Fiscal Year Ended December 31, 2014 [Japan GAAP]</Source><Source id="1629125" type="PR">Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results</Source><Source id="1614432" type="PR">Group of companies "R-Pharm" entered into an agreement with the company "Bristol-Myers Squibb" on the localization of the full cycle of antiretroviral drugs to treat HIV infection</Source><Source id="1611952" type="PR">Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2014 [Japan GAAP]</Source><Source id="1605207" type="PR">Bristol-Myers Squibb Reports Third Quarter 2014 Financial Results</Source><Source id="1585980" type="PR">Bio-Path Holdings Reports Second Quarter 2014 Operational and Financial Results</Source><Source id="1584136" type="PR">Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2014 [Japan GAAP]</Source><Source id="1579910" type="PR">Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results</Source><Source id="1571798" type="PR">Daiichi Sankyo Launches New Generic Drugs Through Its Daiichi Sankyo Espha Subsidiary</Source><Source id="1556755" type="PR">Consolidated Financial Results for the Fiscal Year Ended March 31, 2014 [Japan GAAP]</Source><Source id="1540642" type="PR">Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen® from Eisai (U.S.)</Source><Source id="1524497" type="PR">Consolidated Financial Results for Third Quarter of the Fiscal Year Ending March 31, 2014 [Japan GAAP]</Source><Source id="1518323" type="PR">Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results</Source><Source id="1511760" type="PR">慢性骨髄性白血病の治療薬としてボスチニブ（PF-5208763/SKI-606)の製造販売承認を申請報道関係各位</Source><Source id="1507570" type="PR">Four-Year Data from Phase 3 DASISION Trial Comparing Sprycel (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Presented at Annual Meeting of the American Society of Hematology</Source><Source id="1497735" type="PR">Bristol-Myers Squibb Evolves R&amp;amp;D Strategy</Source><Source id="1491256" type="PR">Bristol-Myers Squibb Reports Third Quarter 2013 Financial Results</Source><Source id="1463283" type="PR">Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2014 [Japan GAAP]</Source><Source id="1447119" type="PR">ARIAD Announces Marketing Authorization for Iclusig (ponatinib) in the European Union</Source><Source id="1442698" type="PR">FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase</Source><Source id="1420199" type="PR">Consolidated Financial Results for the Fiscal Year Ended March 31, 2013 [Japan GAAP]</Source><Source id="1411632" type="PR">PDCO monthly report of opinions on paediatric investigation plans and other activities</Source><Source id="1410186" type="PR">Bristol-Myers Squibb Reports First Quarter 2013 Financial Results</Source><Source id="1397033" type="PR">Pfizer's BOSULIF (bosutinib) Receives Conditional Marketing Authorization From The European Commission</Source><Source id="1394138" type="PR">Moffitt Cancer Center Researchers Study Use of Dasatinib for Patients with High-Risk MDS</Source><Source id="1384346" type="PR">Combo of Avastin, Second Drug Shows Promise Fighting Brain Cancer, Mayo Clinic Finds</Source><Source id="1382613" type="PR">Early results show two drugs may be better than one to treat most deadly skin cancer</Source><Source id="1334357" type="PR">Bristol-Myers Squibb Reports Third Quarter 2012 Financial Results</Source><Source id="1320487" type="PR">U.S. Food and Drug Administration Approves BOSULIF (bosutinib) for Patients with Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML)</Source><Source id="1317791" type="PR">PDCO monthly report of opinions on paediatric investigation plans and other activities15-17 August 2012</Source><Source id="1316814" type="PR">ARIAD Begins Phase 1/2 Trial of Ponatinib in Japan</Source><Source id="1315841" type="PR">Bristol-Myers Squibb Announces Specialty Pharmacy Patient Management Programs For Sprycel (dasatinib) Patients</Source><Source id="1312035" type="PR">Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration</Source><Source id="1310918" type="PR">Bristol-Myers Squibb's Second Quarter Highlighted by the Planned Strategic Acquisition of Amylin Pharmaceuticals and Important Clinical Data in Immuno-Oncology</Source><Source id="1301538" type="PR">Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib</Source><Source id="1291734" type="PR">New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting</Source><Source id="1289744" type="PR">Consolidated Financial Results for the Fiscal Year Ended March 31, 2012 [Japan GAAP]</Source><Source id="1284409" type="PR">Bristol-Myers Squibb Delivers a Solid First Quarter with Strong Operating Results and Key R&amp;amp;D Milestones</Source><Source id="1283362" type="PR">NICE recommends nilotinib and standard dose imatinib for first line chronic myeloid leukaemia</Source><Source id="1279263" type="PR">Bristol Myers executed a co-promotion agreement for Spricel with Otsuka in Japan</Source><Source id="1279260" type="PR">Bristol Myers Squibb received approval about anti-cancer agent Sprycell</Source><Source id="1261742" type="PR">Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2012 [Japan GAAP]</Source><Source id="1246134" type="PR">NICE recommends two drugs for chronic myeloid leukaemia</Source><Source id="1242699" type="PR">Drug Safety Labeling Changes</Source><Source id="1238314" type="PR">Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2012 [Japan GAAP]</Source><Source id="1234134" type="PR">Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development</Source><Source id="1229959" type="PR">Sprycel (dasatinib): Drug Safety Communication - Risk of Pulmonary Arterial Hypertension</Source><Source id="1210870" type="PR">Bristol-Myers Squibb Delivers Excellent Second Quarter with Global New Product Approvals, Important Clinical Data and Strong Financial Results</Source><Source id="1200727" type="PR">Anti-cancer agent "Sprycel 20mg Tablets and Sprycel 50mg Tablets (dasatinib)" approved as the first-line treatment of chronic myeloid leukemia</Source><Source id="1197633" type="PR">Five-Year Follow-Up Data for SPRYCEL (dasatinib) 100 mg Once Daily Demonstrated 78 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant or Intolerant to Gleevec*</Source><Source id="1187080" type="PR">Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY (ipilimumab) Approval, Key R&amp;amp;D Milestones and Strong Financials</Source><Source id="1164022" type="PR">Bristol-Myers Squibb Delivers Solid Fourth Quarter Results in a Year Highlighted by Robust Clinical Data, Continued Execution of Strategic Transactions and Good Operating Performance</Source><Source id="1161464" type="PR">SPRYCEL SHOWS PROMISE AS FIRST LINE THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA</Source><Source id="1156761" type="PR">The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL (dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia</Source><Source id="1154121" type="PR">Follow-Up Results from Study Comparing SPRYCEL (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data</Source><Source id="1153800" type="PR">Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia</Source><Source id="1143062" type="PR">FDA approves SPRYCEL (dasatinib) as treatment for adult patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase</Source><Source id="1142887" type="PR">FDA Approves Additional Medical Indication for Sprycel</Source><Source id="1142172" type="PR">Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance, Robust Clinical Data and the Strategic Acquisition of ZymoGenetics</Source><Source id="1141406" type="PR">Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 18-21 October 2010</Source><Source id="1130423" type="PR">ARIAD Announces Initiation of Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia</Source><Source id="1117905" type="PR">Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth</Source><Source id="1115421" type="PR">SPRYCEL (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase</Source><Source id="1108941" type="PR">FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over gleevec</Source><Source id="1108927" type="PR">FDA approves new indication for Tasigna</Source><Source id="1107059" type="PR">Four-Year Follow-Up Data for SPRYCEL (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec*</Source><Source id="1106604" type="PR">SPRYCEL (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase</Source><Source id="1106350" type="PR">Four-Year Follow-Up Data for SPRYCEL (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec</Source><Source id="1106037" type="PR">SPRYCEL (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase</Source><Source id="1094869" type="PR">Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter</Source><Source id="1071472" type="PR">Strong operational and strategic performance in fourth quarter caps transformative 2009</Source><Source id="1065637" type="PR">Synta Pharmaceuticals initiates phase 2 clinical trial of STA-9090 in gastrointestinal stromal tumors (GIST) following failure of gleevec and sutent</Source><Source id="1051560" type="PR">Meeting highlights from the Paediatric Committee, 14-16 October 2009</Source><Source id="1051308" type="PR">Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter</Source><Source id="1027934" type="PR">Excellent Performance Highlights Second Quarter for Bristol-Myers Squibb</Source><Source id="1012819" type="PR">FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec</Source><Source id="1010146" type="PR">SPRYCEL (Dasatinib) Shows Potential as Treatment for Prostate Cancer</Source><Source id="1003940" type="PR">Bristol-Myers Squibb Reports Excellent First Quarter Financial Results; Delivers on Two Significant Strategic Initiatives</Source><Source id="988269" type="SERIAL">Relevance of multidrug resistance in the age of targeted therapy</Source><Source id="982959" type="SERIAL">Nineteen new medicines launched in 2008</Source><Source id="977559" type="SERIAL">Lacteal Secretion, Fetal and Maternal Tissue Distribution of Dasatinib in Rats</Source><Source id="974275" type="SERIAL">Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors</Source><Source id="972571" type="SERIAL">2 Drugs for CML, 2 Anti-HIV Drugs Recommended for Approval</Source><Source id="970032" type="SERIAL">Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells</Source><Source id="969810" type="SERIAL">Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia</Source><Source id="969799" type="SERIAL">Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro</Source><Source id="961407" type="SERIAL">Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia</Source><Source id="961362" type="SERIAL">Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis</Source><Source id="959774" type="SERIAL">Top-ranking foreign-invested pharmaceutical firms to launch about twenty new drugs in 2008</Source><Source id="956342" type="SERIAL">Dasatinib exerts an immunosuppressive effect on CD8(+) T cells specific for viral and leukemia antigens</Source><Source id="955281" type="SERIAL">Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells</Source><Source id="955280" type="SERIAL">Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFR&amp;agr</Source><Source id="955255" type="SERIAL">Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia</Source><Source id="953635" type="SERIAL">Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer</Source><Source id="951813" type="SERIAL">Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRA(D842V) mutation</Source><Source id="946581" type="SERIAL">Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib</Source><Source id="944835" type="SERIAL">Dasatinib-induced acute hepatitis</Source><Source id="943116" type="SERIAL">Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib</Source><Source id="940645" type="SERIAL">Identification of the human enzymes involved in the oxidative metabolism of dasatinib: An effective approach for determining metabolite formation kinetics</Source><Source id="939504" type="SERIAL">Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib</Source><Source id="939485" type="SERIAL">Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib</Source><Source id="939475" type="SERIAL">Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia</Source><Source id="939468" type="SERIAL">The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgV(H)genes</Source><Source id="936693" type="SERIAL">Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia</Source><Source id="933373" type="SERIAL">Centrosome aberrations and G(1) phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib</Source><Source id="928002" type="SERIAL">Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib</Source><Source id="926744" type="SERIAL">Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia</Source><Source id="926309" type="SERIAL">Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis</Source><Source id="924088" type="SERIAL">Ten original new drugs to enter the Korean market in 2007</Source><Source id="922783" type="SERIAL">Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications</Source><Source id="922781" type="SERIAL">Biotransformation of [(14)C]dasatinib: In vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys</Source><Source id="922755" type="SERIAL">Phase II study of dasatinib in Philadelphia chromosome - negative acute and chronic myeloid diseases, including systemic mastocytosis</Source><Source id="922456" type="SERIAL">Metabolism and disposition of dasatinib after oral administration to humans</Source><Source id="922438" type="SERIAL">Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib</Source><Source id="915513" type="SERIAL">Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones</Source><Source id="914163" type="SERIAL">Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib</Source><Source id="908984" type="SERIAL">Targeting src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model</Source><Source id="908204" type="SERIAL">Novel chromosomal aberration in Philadelphia negative cells of a patient with chronic myelogenous leukemia treated with dasatinib</Source><Source id="906752" type="SERIAL">Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines</Source><Source id="906711" type="SERIAL">Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure</Source><Source id="906275" type="SERIAL">Profound inhibition of antigen-specific T-cell effector functions by dasatinib</Source><Source id="902951" type="SERIAL">Dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression, in contrast to imatinib</Source><Source id="902923" type="SERIAL">Nilotinib in chronic myelogenous leukaemia patients who failed prior imatinib and dasatinib therapy: updated results of an open-label phase 2 study</Source><Source id="902905" type="SERIAL">Despite treatment with high dose dasatinib in the absence of growth factors, CML stem cells survive for 12 days in vitro</Source><Source id="901593" type="SERIAL">Initial testing of dasatinib by the Pediatric Preclinical Testing Program</Source><Source id="900913" type="SERIAL">Profound inhibition of antigen-specific T-cell effector functions by dasatinib</Source><Source id="897787" type="SERIAL">Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors</Source><Source id="897768" type="SERIAL">New strategies for the first-line treatment of chronic myeloid leukemia: Can resistance be avoided</Source><Source id="897763" type="SERIAL">Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia</Source><Source id="897760" type="SERIAL">Optimizing treatment with bcr-abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: Focus on dosing schedules</Source><Source id="897422" type="SERIAL">Sequential mutations causing resistance to both imatinib mesylate and dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis</Source><Source id="897391" type="SERIAL">Dasatinib - In chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia</Source><Source id="897353" type="SERIAL">Dasatinib therapy for systemic mastocytosis: four cases</Source><Source id="892487" type="SERIAL">The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils</Source><Source id="880797" type="SERIAL">Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation</Source><Source id="874833" type="SERIAL">Role of dasatinib in PH'-positive acute lymphoblastic leukemia (ALL) after imatinib-based therapy failure: A case report</Source><Source id="871190" type="SERIAL">Nilotinib and dasatinib, two novel and more potent inhibitors of c-abl and pdgf signalling, for the treatment of experimental dermal fibrosis</Source><Source id="867185" type="SERIAL">Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL</Source><Source id="865220" type="SERIAL">Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors</Source><Source id="860450" type="SERIAL">Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680</Source><Source id="854079" type="SERIAL">Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT</Source><Source id="852611" type="SERIAL">Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative'' breast cancer cell lines growing in vitro</Source><Source id="851873" type="SERIAL">Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study</Source><Source id="848568" type="SERIAL">Lung abnormalities after dasatinib treatment for chronic myeloid leukemia - A case series</Source><Source id="847769" type="SERIAL">Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy</Source><Source id="843891" type="SERIAL">Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation</Source><Source id="838834" type="SERIAL">Sorafenib inhibits the imatinib-resistant KIT(T6701) gatekeeper mutation in gastrointestinal stromal tumor</Source><Source id="831543" type="SERIAL">BCR-ABL mutant kinetics in CML patients treated with dasatinib</Source><Source id="827678" type="SERIAL">Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects</Source><Source id="822342" type="SERIAL">Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial</Source><Source id="820542" type="SERIAL">Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure</Source><Source id="819188" type="SERIAL">L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition</Source><Source id="816596" type="SERIAL">American Society of Clinical Oncology - 43rd Annual Meeting. Research into therapeutics: Part 4</Source><Source id="813760" type="SERIAL">Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy</Source><Source id="805514" type="SERIAL">MEK1/2 inhibitors sensitize Bcr/Abl(+) human leukemia cells to the dual Abl/Src inhibitor BMS-354/825</Source><Source id="800208" type="SERIAL">Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis</Source><Source id="791810" type="SERIAL">Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI)</Source><Source id="789979" type="SERIAL">Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy</Source><Source id="789913" type="SERIAL">Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival</Source><Source id="783625" type="SERIAL">Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection</Source><Source id="781468" type="SERIAL">c-Src protein kinase inhibitors block assembly and maturation of dengue virus</Source><Source id="767009" type="SERIAL">Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias</Source><Source id="764227" type="SERIAL">Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN 107) therapy failure</Source><Source id="764226" type="SERIAL">MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation</Source><Source id="762056" type="SERIAL">Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib</Source><Source id="760664" type="SERIAL">New product: Sprycel</Source><Source id="756520" type="SERIAL">Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure</Source><Source id="750867" type="SERIAL">Dasatinib (Sprycel) Therapy for Patients with Systemic Mastocytosis</Source><Source id="750864" type="SERIAL">Sustained Molecular Responses to Dasatanib (SPRYCEL) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience</Source><Source id="750860" type="SERIAL">Dasatinib (SPRYCEL) in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results from the CA180-015 START-L Study</Source><Source id="749993" type="SERIAL">Centrosome aberrations, disturbed mitotic spindle formation and G1 arrest in normal and leukemic cells treated with the SRC/ABL inhibitor dasatinib</Source><Source id="749991" type="SERIAL">Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development</Source><Source id="749984" type="SERIAL">Dasatinib (SPRYCEL) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i)</Source><Source id="749982" type="SERIAL">Dasatinib (SPRYCEL) 140 mg Once Daily (QD) vs 70 mg Twice Daily (BID) in Patients (pts) with Advanced Phase Chonic Myeloid Leukemia (ABP-CML) or Ph(+) ALL Who Are Resistant or Intolerant to Imatinib (im): Results of the CA180-035 Study</Source><Source id="749978" type="SERIAL">Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations</Source><Source id="749974" type="SERIAL">Combination of the Histone Deacetylase Inhibitor Vorinostat and Dasatinib Increases Apoptosis in Bcr-abl+ Cells and Reverses Changes Associated with CML Progression</Source><Source id="749961" type="SERIAL">Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure</Source><Source id="749959" type="SERIAL">Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCEL(R)): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy</Source><Source id="749957" type="SERIAL">Dasatinib (SPRYCEL) in Children and Adolescents with Relapsed or Refractory Leukemia: Preliminary Results of the CA180018 Phase I/II Study</Source><Source id="749955" type="SERIAL">Dasatinib (SPRYCEL) in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase (CML-CP).</Source><Source id="749949" type="SERIAL">Dasatinib (SPRYCEL(R)) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180-005 START-A Phase II Study</Source><Source id="749627" type="SERIAL">Council Urges Quick Development and Approval of 3 Drugs</Source><Source id="749602" type="SERIAL">Jak2: A Potential Therapeutic Target for Chronic Myelogenous Leukemia (CML)</Source><Source id="749596" type="SERIAL">Dynamics of Cytogenetic Aberrations in Philadelphia Chromosome Positive and Negative Hematopoiesis during Dasatinib Therapy of Chronic Myeloid Leukemia Patients after Imatinib Failure</Source><Source id="748100" type="SERIAL">Dasatinib (SPRYCEL) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study</Source><Source id="748098" type="SERIAL">Dasatinib (SPRYCEL(R)) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study</Source><Source id="748089" type="SERIAL">Efficacy of Dasatinib (SPRYCEL(R)) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 'START-C' Phase II Study</Source><Source id="747746" type="SERIAL">Mechanism of Drug Resistance to Dasatinib (BMS-354825) and Imatinib in Chronic Myelogenous Leukemia Cells</Source><Source id="747725" type="SERIAL">Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils</Source><Source id="744557" type="SERIAL">Effect of the SRC tyrosine kinase inhibitor dasatinib in combination with erlotinib and in cells with acquired resistance to erlotinib</Source><Source id="744049" type="SERIAL">Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias</Source><Source id="741548" type="SERIAL">Mass balance, pharmacokinetics and metabolism of [14C] BMS-354825 in healthy male subjects     </Source><Source id="740349" type="SERIAL">Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis</Source><Source id="739576" type="SERIAL">Pediatric Preclinical Testing Program (PPTP) Evaluation of the Src-Abl Inhibitor Dasatinib (BMS-354825)</Source><Source id="739543" type="SERIAL">Dasatinib (BMS-354825), a novel, potent inhibitor of Bcr-Abl and Src, has a significant migration effect on human neuroblastoma and Ewing sarcoma cells</Source><Source id="739504" type="SERIAL">A Phase I Study of dasatinib, a Src and multi- kinase inhibitor, in patients (pts) with GIST and other solid tumors</Source><Source id="739466" type="SERIAL">Effects of dasatinib on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in healthy subjects</Source><Source id="735887" type="SERIAL">Cotreatment with vorinostat (Suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells</Source><Source id="734719" type="SERIAL">Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations</Source><Source id="728427" type="SERIAL">Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML</Source><Source id="688215" type="SERIAL">2-Aminothiazole: A novel template for the discovery of Dasatinib (BMS-354825), a pan Src/Abl kinase inhibitor</Source><Source id="676059" type="SERIAL">The identification of new protein kinase inhibitors as targets in modern drug discovery</Source><Source id="671458" type="SERIAL">Effect of dasatinib, a SRC kinase inhibitor, on lung cancer cells with defined epidermal growth factor receptor status</Source><Source id="670422" type="SERIAL">Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003)</Source><Source id="670042" type="SERIAL">K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (PTS) with residual disease on imatinib mesylate (IM)</Source><Source id="670040" type="SERIAL">Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 'START-C' Study</Source><Source id="670037" type="SERIAL">Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial</Source><Source id="669033" type="SERIAL">Dasatinib (BMS354825), a dual Src-Abl inhibitor, is active in Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) following treatment failure with imatinib mesylate and AMN107</Source><Source id="669031" type="SERIAL">Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 'START-B' study</Source><Source id="669030" type="SERIAL">Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study</Source><Source id="669029" type="SERIAL">Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study</Source><Source id="669027" type="SERIAL">Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib</Source><Source id="659941" type="SERIAL">Development of the ABL kinase inhibitor dasatinib (BMS-354825) in imatinib-resistant Philadelphia chromosome positive leukemias</Source><Source id="659656" type="SERIAL">Combined activity of dasatinib (BMS-354825) and oxaliplatin in an orthotopic model of metastatic colorectal carcinoma</Source><Source id="659647" type="SERIAL">Dasatinib (BMS-354825), a novel multi-targeted kinase inhibitor that blocks tumor cell migration and invasion, is a promising therapeutic agent for metastatic prostate cancer</Source><Source id="659644" type="SERIAL">Dasatinib (BMS-354825) inhibits stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells</Source><Source id="659637" type="SERIAL">Dasatinib (BMS-354825) inhibits migration and invasion of human melanoma cells and is a promising therapeutic agent for metastatic melanoma</Source><Source id="641786" type="SERIAL">Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies</Source><Source id="641262" type="SERIAL">A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 'START-B' Study</Source><Source id="641258" type="SERIAL">Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 'START-A' Study</Source><Source id="641256" type="SERIAL">Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study</Source><Source id="640974" type="SERIAL">Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro, but Does Not Eradicate Quiescent CML Stem Cells</Source><Source id="640534" type="SERIAL">Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML)</Source><Source id="640532" type="SERIAL">Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity</Source><Source id="639974" type="SERIAL">Efficacy of dasatinib in patients with chronic phase philadelphia chromosome-positive CML resistant or intolerant to imatinib: first results of the CA180013 'START-C' phase II study</Source><Source id="639863" type="SERIAL">Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma</Source><Source id="638672" type="SERIAL">Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy</Source><Source id="638669" type="SERIAL">Correlation of Clinical Response to Dasatinib (BMS-354825) with BCR-ABL Mutation Status in Imatinib- Resistant Patients (pts) with Chronic Myeloid Leukemia (CML) Treated at MD Anderson Cancer Center (MDACC)</Source><Source id="637466" type="SERIAL">Targeted Overexpression of Activated Human c-SRC in Transgenic Mice Results in Mammary Tumors that are Highly Sensitive to the Novel, Oral, Multitargeted Kinase Inhibitor Dasatinib (BMS-354825)</Source><Source id="636875" type="SERIAL">Evaluation of Anti-osteoclastic Activity of the Novel, Oral Multi-targeted Kinase Inhibitor Dasatinib (BMS-354825)</Source><Source id="636785" type="SERIAL">Dasatinib (BMS-354825) Inhibits Stat5 Signaling associated with Apoptosis in Chronic Myelogenous Leukemia Cells</Source><Source id="636782" type="SERIAL">Action of Dasatinib (BMS-354825), a Novel, Oral, Multi-targeted Kinase Inhibitor, on Human Prostate Cancer Cells</Source><Source id="636779" type="SERIAL">Co-treatment with the Novel, Oral, Multi-targeted Kinase Inhibitor,Dasatinib (BMS-354825) and the Histone Deacetylase Inhibitor Corinostat(suberoylanilide hydroxamic acid, SAHA): A Highly Active Combinationagainst Wild-type or Mutant Bcr-Abl-T315I containing Human Leukemia Cells</Source><Source id="636717" type="SERIAL">Identification of Potential Biomarkers for Measuring the Pharmacological Inhibition of SRC Kinase Activity Following Treatment with Dasatinib(BMS-354825), a Multi-targeted Kinase Inhibitor</Source><Source id="636713" type="SERIAL">Biologic Effects and Identification of Predictive Markers of Response to Dasatinib (BMS-354825), a Novel, Oral, Multi-targeted Kinase Inhibitor in Human Breast Cancer Cell Lines in vitro</Source><Source id="631268" type="SERIAL">Patent alert</Source><Source id="625657" type="SERIAL">Paper alert</Source><Source id="618952" type="SERIAL">Paper alert</Source><Source id="616582" type="SERIAL">Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays</Source><Source id="608574" type="SERIAL">PharmaDiscovery 2005. Kinases in drug discovery</Source><Source id="608562" type="SERIAL">American Society of Clinical Oncology - 41st Annual Meeting</Source><Source id="603651" type="SERIAL">BMS-354825 induced complete hematologic remission in chronic phase CML patients without affecting T-cell cytokine production</Source><Source id="603643" type="SERIAL">Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors</Source><Source id="603637" type="SERIAL">Correlation of Clinical Response to BMS-354825 with BCR-ABL Mutation Status in Imatinib-Resistant Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Associated Acute Lymphoblastic Leukemia (Ph+ ALL)</Source><Source id="603631" type="SERIAL">A Phase I Study of BMS-354825 in Patients with Imatinib-Resistant and Intolerant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML): Results from CA180002</Source><Source id="603629" type="SERIAL">A Phase I Study of BMS-354825 in Patients with Imatinib-Resistant and Intolerant Chronic Phase Chronic Myeloid Leukemia (CML): Results from CA180002</Source><Source id="603624" type="SERIAL">Identification of Pharmacogenomic Markers for Predicting Sensitivity to BMS-354825, a SRC/ABL Kinase Inhibitor</Source><Source id="597205" type="SERIAL">Anglo-Swedish Medicinal Chemistry - Second Symposium</Source><Source id="593431" type="SERIAL">BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo</Source><Source id="593430" type="SERIAL">BMS-354825 multiple oncogenic tyrosine kinase inhibitor induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) cells</Source><Source id="587201" type="SERIAL">Paper alert</Source><Source id="574299" type="SERIAL">The Dual SRC/ABL Kinase Inhibitor BMS-354825 Potently Inhibits the Growth of Myeloid Leukemic Cells Characterized by Flt3-ITD Expression, GM-CSF Dependency, or G-CSF Responsiveness Via an ABL-Independent Mechanism</Source><Source id="574256" type="SERIAL">BMS-354825 Is a SRC/ABL Inhibitor with High Nanomolar Activity Against the Kit D816v Mutation, Which Drives Systemic Mastocytosis and Is Imatinib-Resistant</Source><Source id="573952" type="SERIAL">The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor</Source><Source id="573940" type="SERIAL">Comparative Analysis of Two BCR-ABL Small Molecule Inhibitors Reveals Overlapping but Distinct Mechanisms of Resistance</Source><Source id="573737" type="SERIAL">BMS-354825 Potently Inhibits the Kinase Activity of KIT Activation Loop Mutations Associated with Systemic Mastocytosis and Induces Apoptosis of Mastocytosis Cell Lines</Source><Source id="573146" type="SERIAL">The SRC/ABL Inhibitor BMS-354825 Overcomes Resistance to Imatinib Mesylate in Chronic Myelogenous Leukemia Cells through Multiple Mechanisms</Source><Source id="573139" type="SERIAL">BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth</Source><Source id="573134" type="SERIAL">Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825</Source><Source id="573118" type="SERIAL">Simultaneous Targeting of SRC and BCR-ABL Kinases by BMS-354825 Cures Ph+ Acute Lymphoblastic Leukemia in Mice</Source><Source id="572698" type="SERIAL">Hematologic and Cytogenetic Responses in Imatinib-Resistant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study</Source><Source id="572682" type="SERIAL">Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study</Source><Source id="572164" type="SERIAL">Major Cytogenetic Responses to BMS-354825 in Patients with Chronic Myeloid Leukemia Are Associated with a One to Two Log Reduction in BCR-ABL Transcript</Source><Source id="564293" type="SERIAL">Targeting Bcr/Abl and Src family kinases reverses Imatinib mesylate resistance in CML</Source><Source id="554989" type="SERIAL">Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance</Source><Source id="554988" type="SERIAL">Overriding imatinib resistance with a novel ABL kinase inhibitor</Source><Source id="531143" type="SERIAL">BMS-354825 - A potent dual SRC/ABL kinase inhibitor possessing curative efficacy against imatinib sensitive and resistant human CML models in vivo </Source><Source id="531140" type="SERIAL">The SRC/ABL kinase inhibitor BMS-354825 induces apoptosis and overcomes imatinib resistance in chronic myelogenous leukemia cell lines and patient specimens</Source><Source id="530605" type="SERIAL">BMS-354825 is a novel orally bioavailable small molecule ABL tyrosine kinase inhibitor that successfully and safely inhibits the kinase activity of multiple imatinib-resistant BCR-ABL isoforms in vitro and in vivo </Source><Source id="2053989" type="SERIAL">Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase ii trial</Source><Source id="1804981" type="SERIAL">Final 5-year study results of dasision: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial</Source><Source id="1588433" type="SERIAL">Generic Imatinib: The real-deal or just a deal?</Source><Source id="1588432" type="SERIAL">Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy</Source><Source id="1588403" type="SERIAL">Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib</Source><Source id="1508289" type="SERIAL">A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC)</Source><Source id="1467905" type="SERIAL">Phase I trial, pharmacokinetics,and pharmacodynamics of vandetanib and dasatinib in children with newlydiagnosed diffuse intrinsic pontine glioma</Source><Source id="1340482" type="SERIAL">Dasatinib, Sprycel tablets (Bristol Myers Squibb)</Source><Source id="1325412" type="SERIAL">Triangular competition expected in the Korean market for first-line treatments of chronic myeloid leukemia</Source><Source id="1313295" type="SERIAL">Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies</Source><Source id="1309502" type="SERIAL">Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma</Source><Source id="1286511" type="SERIAL">Dasatinib inhibits pro-inflammatory functions of mature human neutrophils</Source><Source id="1285863" type="SERIAL">Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients</Source><Source id="1278160" type="SERIAL">Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601) A Brief Report</Source><Source id="1272198" type="SERIAL">Spotlight on Dasatinib in Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</Source><Source id="1270031" type="SERIAL">Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia</Source><Source id="1268188" type="SERIAL">Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)</Source><Source id="1264993" type="SERIAL">Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia</Source><Source id="1261894" type="SERIAL">Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma</Source><Source id="1255777" type="SERIAL">Dasatinib combined with docetaxel for castration-resistant prostate cancer</Source><Source id="1255223" type="SERIAL">Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia</Source><Source id="1248721" type="SERIAL">Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study</Source><Source id="1248720" type="SERIAL">A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer</Source><Source id="1243591" type="SERIAL">Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors</Source><Source id="1233787" type="SERIAL">Dasatinib A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia</Source><Source id="1227519" type="SERIAL">Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing</Source><Source id="1217805" type="SERIAL">KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib</Source><Source id="1217558" type="SERIAL">Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib</Source><Source id="1207604" type="SERIAL">Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-0-15)</Source><Source id="1207516" type="SERIAL">Recent advances in small molecule inhibitors of vegfr and egfr signaling pathways</Source><Source id="1201115" type="SERIAL">The abl switch control inhibitor dcc-2036 is active against the chronic myeloid leukemia mutant bcr-abl(t315i) and exhibits a narrow resistance profile</Source><Source id="1199761" type="SERIAL">Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: a two-year update of the START-C study</Source><Source id="1199760" type="SERIAL">Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015)</Source><Source id="1197676" type="SERIAL">Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib</Source><Source id="1197351" type="SERIAL">BMS Korea’s Sprycel 100mg tab. for the treatment of leukemia approved by the KFDA</Source><Source id="1195386" type="SERIAL">Navigating the road toward optimal initial therapy for chronic myeloid leukemia</Source><Source id="1195381" type="SERIAL">Imatinib and beyond—exploring the full potential of targeted therapy for CML</Source><Source id="1194730" type="SERIAL">Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)</Source><Source id="1194134" type="SERIAL">A phase 2 trial of dasatinib in advanced melanoma</Source><Source id="1192437" type="SERIAL">Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia</Source><Source id="1192429" type="SERIAL">Treatment selection after imatinib resistance in chronic myeloid leukemia</Source><Source id="1192426" type="SERIAL">New dosing schedules of dasatinib for CML and adverse event management</Source><Source id="1192407" type="SERIAL">Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia</Source><Source id="1192251" type="SERIAL">ABC of clinical haematology: chronic myeloid leukaemia</Source><Source id="1188274" type="SERIAL">Docetaxel-based combination therapy for castration-resistant prostate cancer</Source><Source id="1177796" type="SERIAL">Pediatric phase I trial and pharmacokinetic study of dasatinib: A report from the children's oncology group phase I consortium</Source><Source id="1176559" type="SERIAL">Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor</Source><Source id="1172474" type="SERIAL">Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.</Source><Source id="1160176" type="SERIAL">Sprycel obtains EC approval for a new indication</Source><Source id="1146963" type="SERIAL">The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance</Source><Source id="1146780" type="SERIAL">Chemical proteomic profiles of the Bcr-Abl inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets</Source><Source id="1144073" type="SERIAL">Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction</Source><Source id="1139855" type="SERIAL">Protein kinase inhibitors: Contributions from structure to clinical compounds</Source><Source id="1137489" type="SERIAL">First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia</Source><Source id="1136896" type="SERIAL">Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: For overriding Bcr-Abl/T315I. From the second to third generation</Source><Source id="1133814" type="SERIAL">Standard treatment of Ph+ CML in 2010: How, when and where not to use what BCR/ABL1 kinase inhibitor</Source><Source id="1124099" type="SERIAL">The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo</Source><Source id="1124098" type="SERIAL">Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.</Source><Source id="1124095" type="SERIAL">The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up</Source><Source id="1124078" type="SERIAL">NS-187 (INNO-406), a BCR-ABL1/Lyn dual tyrosine kinase inhibitor</Source><Source id="1124071" type="SERIAL">Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib</Source><Source id="1124070" type="SERIAL">Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase</Source><Source id="1124069" type="SERIAL">Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase</Source><Source id="1124059" type="SERIAL">SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.</Source><Source id="1110613" type="SERIAL">Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias</Source><Source id="1109062" type="SERIAL">Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia</Source><Source id="1109057" type="SERIAL">New targeted therapies for chronic myelogenous leukemia: Opportunities to overcome imatinib resistance</Source><Source id="1109035" type="SERIAL">The second generation of BCR-ABL tyrosine kinase inhibitors</Source><Source id="1106136" type="SERIAL">Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia</Source><Source id="1087503" type="SERIAL">Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis</Source><Source id="1085089" type="SERIAL">Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study</Source><Source id="1063935" type="SERIAL">Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations</Source><Source id="1054441" type="SERIAL">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</Source><Source id="1044253" type="SERIAL">Small molecules and targeted therapies in distant metastatic disease</Source><Source id="1030713" type="SERIAL">The btk tyrosine kinase is a major target of the bcr-abl inhibitor dasatinib</Source><Source id="1024700" type="SERIAL">Innovative phase I-II study of concomitant and consecutive treatment with Dasatinib and MK-0457 in refractory Ph+ CML and ALL patients</Source><Source id="1022475" type="SERIAL">Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up</Source><Source id="1008740" type="SERIAL">Bristol-Myers: Sprycel for CML and ALL</Source><Source id="998350" type="CONFERENCE">PharmaSource 2009, Global Sourcing Strategies for the Pharmaceutical Industry, Berlin, Germany</Source><Source id="974119" type="CONFERENCE">San Antonio Breast Cancer Symposium – 31st Annual Symposium (Part II), San Antonio, TX, USA</Source><Source id="972530" type="CONFERENCE">Summary of the American Society of Hematology 50th Annual Meeting, San Francisco, CA, USA</Source><Source id="969013" type="CONFERENCE">American Society of Hematology – 50th Annual Meeting and Exposition (Part I) - OVERNIGHT REPORT, San Francisco, CA, USA</Source><Source id="967240" type="CONFERENCE">Preview of the American Society of Hematology 50th Annual Meeting and Exposition, San Francisco, CA, USA</Source><Source id="963212" type="CONFERENCE">Biomarkers Europe 2008 - CHI's Third Annual Conference, Vienna, Austria</Source><Source id="942209" type="CONFERENCE">Medicinal Chemistry – XXth International Symposium (Part III), Lead finding strategies and kinase selectivity, Vienna, Austria</Source><Source id="931244" type="CONFERENCE">Genitourinary Malignancies - Eighth International Congress (Part II), The Changing Face of Prostate Cancer – Novel Agents at Work, Washington DC, USA</Source><Source id="922322" type="CONFERENCE">Protein Kinase Targets – CHI's Sixth Annual Conference, Drug Discovery and Design, Boston, MA, USA</Source><Source id="919161" type="CONFERENCE">Summary of the American Society of Clinical Oncology - 44th Annual Meeting, Chicago, IL USA</Source><Source id="910185" type="CONFERENCE">Sarcoma and GIST - Second European Society for Medical Oncology Symposium, Insight at the crossroads of molecular biology, pathology, and the clinic, Milan, Italy</Source><Source id="902209" type="CONFERENCE">Summary of the American Association for Cancer Research - 99th Annual Meeting, San Diego, CA, USA</Source><Source id="899010" type="CONFERENCE">Biomarkers in Drug Development – ACI's Second Conference, London, UK</Source><Source id="889288" type="CONFERENCE">Protein Kinases - Informa's Seventh Annual Congress (Part II), Berlin, Germany</Source><Source id="862666" type="CONFERENCE">Summary of the American Society of Hematology - 49th Annual Meeting, Atlanta, GA, USA</Source><Source id="858982" type="CONFERENCE">American Society of Hematology - 49th Annual Meeting and Exposition (Part II) - OVERNIGHT REPORT, Atlanta, GA, USA</Source><Source id="853830" type="CONFERENCE">Myeloproliferative and Myelodysplastic Syndromes - Fourth International Congress, Brooklyn, NY, USA</Source><Source id="850164" type="CONFERENCE">Biomarkers Europe - CHI's Second Annual Conference (Part II), Vienna, Austria</Source><Source id="844994" type="CONFERENCE">Discovery on Target 2007 - CHI's Fifth Annual Conference (Part III), Kinase Inhibitors, Boston, MA, USA</Source><Source id="840244" type="CONFERENCE">Compound Profiling and Chemogenomic Approaches - CHI's Inaugural Conference, Philadelphia, PA, USA</Source><Source id="827762" type="CONFERENCE">Advances in Synthetic and Medicinal Chemistry (ASMC 2007) - International Symposium (Part I), St Petersburg, Russia</Source><Source id="825650" type="CONFERENCE">American Chemical Society - 234th National Meeting (Part X), Boston, MA, USA</Source><Source id="806096" type="CONFERENCE">Protein Kinase Targets - CHI's Fifth Annual Meeting, Boston, MA, USA</Source><Source id="804112" type="CONFERENCE">Protein Kinase in Drug Discovery - GTCbio's Second Annual Conference (Part II), Boston, MA</Source><Source id="801275" type="CONFERENCE">American Society of Clinical Oncology - 43rd Annual Meeting (Part IV) - OVERNIGHT REPORT, Translating Research into Practice, Chicago, IL, USA</Source><Source id="799079" type="CONFERENCE">Protein Kinase 2007: More Signaling Success - Second RSC-SCI Symposium on Kinase Inhibitor Design (Part II), Oss, the Netherlands</Source><Source id="793440" type="CONFERENCE">Pharmaceutical Sciences World Congress 2007(Part II), Amsterdam, the Netherlands</Source><Source id="790864" type="CONFERENCE">Molecular Diagnostics World Congress 2007 - Select Biosciences Conference, Philadelphia, PA, USA</Source><Source id="789014" type="CONFERENCE">American Association for Cancer Research 98th Annual Meeting (Part XII), Los Angeles, CA, USA</Source><Source id="775886" type="CONFERENCE">Targeted Anticancer Therapies – Fifth International Symposium, Amsterdam, The Netherlands (Part I)</Source><Source id="766652" type="CONFERENCE">Chemistry in Cancer Research: A Vital Partnership - A Joint Conference of the AACR and ACS (Part II), Drug Discovery Sessions, San Diego, CA, USA</Source><Source id="752808" type="CONFERENCE">Summary of the American Society of Hematology - 48th Annual Meeting, Orlando, FL, USA</Source><Source id="741576" type="CONFERENCE">Assays &amp;amp; Cellular Targets 2006 – IBC Conference (Part II), Protein Kinase Targets: Challenges and Advances in Drug Development Targeting Kinases, Las Vegas, NV, USA</Source><Source id="678247" type="CONFERENCE">Lung Cancer - Seventh International Congress, Maui, HI, USA</Source><Source id="676330" type="CONFERENCE">Clinical Trials in Cancer - SMi's Fifth Annual Conference, London, UK</Source><Source id="674782" type="CONFERENCE">Summary of the American Society of Clinical Oncology - 42nd Annual Meeting, Atlanta, GA, USA</Source><Source id="669543" type="CONFERENCE">Biomarker World Congress 2006, Philadelphia, PA, 16 - 18 May 2006</Source><Source id="662934" type="CONFERENCE">Summary of the American Association for Cancer Research - 97th Annual Meeting, Washington DC, USA</Source><Source id="662653" type="CONFERENCE">American Association For Cancer Research - 97th Annual Meeting (Part XI), Washington DC, USA</Source><Source id="651617" type="CONFERENCE">Regional Cancer Consortium for the Biological Therapy of Cancer- Ninth Annual Meeting, Pittsburgh, PA, USA</Source><Source id="650448" type="CONFERENCE">Anti-Angiogenic Agents - Eighth International Symposium, Recent Advances and Future Directions in Basic and Clinical Cancer Research, San Diego, CA, USA</Source><Source id="643913" type="CONFERENCE">Summary of the American Society of Hematology - 47th Annual Meeting and Exposition, Atlanta, GA, USA</Source><Source id="639755" type="CONFERENCE">American Society of Hematology - 47th Annual Meeting and Exposition (Part II) - OVERNIGHT REPORT, Atlanta, GA, USA</Source><Source id="639598" type="CONFERENCE">Summary of the 17th AACR-NCI-EORTC Symposium, Molecular Targets and Cancer Therapeutics</Source><Source id="633822" type="CONFERENCE">Preview of the AACR-NCI-EORTC Conference, Molecular Targets and Cancer Therapeutics, Philadelphia, PA, USA</Source><Source id="605112" type="CONFERENCE">Summary of the American Society of Clinical Oncology - 41st Annual Meeting, Orlando, FL, USA</Source><Source id="603756" type="CONFERENCE">PharmaDiscovery 2005, Kinases in Drug Discovery, Washington, DC, USA</Source><Source id="601700" type="CONFERENCE">American Society of Clinical Oncology - 41st Annual Meeting (Part VI) – OVERNIGHT REPORT, Orlando, FL, USA</Source><Source id="599871" type="CONFERENCE">Summary of the American Association for Cancer Research - 96th Annual Meeting, Anaheim, CA, USA</Source><Source id="595569" type="CONFERENCE">American Association for Cancer Research - 96th Annual Meeting (Part IV) - OVERNIGHT REPORT, Anaheim, CA, USA</Source><Source id="594487" type="CONFERENCE">Preview of the American Association for Cancer Research 96th Annual Meeting, Anaheim, CA, USA, 16-20 April 2005</Source><Source id="593130" type="CONFERENCE">Anglo-Swedish Medicinal Chemistry - Second Symposium, Are Fjallby, Sweden</Source><Source id="577201" type="CONFERENCE">Summary of the American Society of Hematology - 46th Annual Meeting and Exposition, San Diego, CA, USA</Source><Source id="575486" type="CONFERENCE">American Society of Hematology - 46th Annual Meeting and Exposition (Part V), San Diego, CA, USA</Source><Source id="574589" type="CONFERENCE">American Society of Hematology - 46th Annual Meeting and Exposition (Part III) - OVERNIGHT REPORT, San Diego, CA, USA</Source><Source id="572641" type="CONFERENCE">Protein kinase targets - IBC Conference, Innovations, Opportunities and Real Case Studies, Amsterdam, the Netherlands</Source><Source id="572268" type="CONFERENCE">Preview of the American Society of Hematology - 46th Annual Meeting and Exposition, San Diego, CA, USA</Source><Source id="566214" type="CONFERENCE">Summary of the 16th EORTC-NCI-AACR Symposium, Molecular Targets and Cancer Therapeutics, Geneva, Switzerland</Source><Source id="561480" type="CONFERENCE">Pharmacology - Fourth Croatian Congress, Split, Croatia</Source><Source id="534019" type="CONFERENCE">Summary of American Association for Cancer Research - 95th Annual Meeting, Orlando, FL, USA</Source><Source id="2164867" type="CONFERENCE">European Hematology Association 24th Annual Congress (Part I), OVERNIGHT REPORT, Amsterdam, Netherlands</Source><Source id="2038396" type="CONFERENCE">Kinase 2018: Towards New Frontiers – Eighth RSC/SCI Symposium on Kinase Inhibitor Design (Part I), Cambridge, UK</Source><Source id="2008461" type="CONFERENCE">GTCBio Enzymes in Drug Discovery 2018: Protein Kinases in Drug Discovery - San Diego, CA, USA</Source><Source id="1954869" type="CONFERENCE">American Chemical Society – 254th National Meeting and Exhibition (Part I) – OVERNIGHT REPORT, Washington DC, USA</Source><Source id="1900983" type="CONFERENCE">GTCBio's 2017 Enzymes in Drug Discovery Summit - 12th Protein Kinases in Drug Discovery, San Diego, CA, USA</Source><Source id="1742788" type="CONFERENCE">Protein Kinases in Drug Discovery - GTCBio's 11th Conference, San Diego, CA, USA</Source><Source id="1731478" type="CONFERENCE">SCI's New Approaches in Medicinal Chemistry Symposium, Stevenage, UK</Source><Source id="1563440" type="CONFERENCE">Kinase 2014: Past, Present and Beyond - Sixth RSC/SCI Symposium on Kinase Inhibitor Design (Part I), Cambridge, UK</Source><Source id="1442968" type="CONFERENCE">Next-Gen Kinase Inhibitors: Moving Towards a Successful Pipeline - CHI's Eleventh Annual Meeting (Part I), Boston, MA, USA</Source><Source id="1426801" type="CONFERENCE">Choosing the Right Target in Drug Discovery - A SCI Meeting, London, UK</Source><Source id="1384502" type="CONFERENCE">Genitourinary Cancers Symposium 2013: A Transformative Multidisciplinary Approach (Part I), Prostate Cancer, Orlando, FL, USA</Source><Source id="1382995" type="CONFERENCE">Molecular Med Tri-Con 2013 (Part II) - Targeting Cancer Stem Cells - CHI's Second Annual Symposia, San Francisco, CA, USA</Source><Source id="1318374" type="CONFERENCE">Mechanisms &amp; Models of Cancer - Ninth Biennial Meeting, Cold Spring Harbor, NY, USA</Source><Source id="1304431" type="CONFERENCE">ENDO 2012 - The 94th Annual Meeting &amp; Exposition of the Endocrine Society (Part IV) - OVERNIGHT REPORT, Houston, TX, USA</Source><Source id="1296085" type="CONFERENCE">Protein Kinase 2012 - Signaling Success: Fifth SCI-RSC Symposium on Kinase Inhibitor Design (Part II), Cambridge, UK</Source><Source id="1252820" type="CONFERENCE">Summary of American Society of Hematology (ASH) - 53rd Annual Meeting and Exposition, San Diego, CA, USA</Source><Source id="1250791" type="CONFERENCE">American Society of Hematology - 53rd Annual Meeting and Exposition (Part IV), San Diego, CA, USA</Source><Source id="1237523" type="CONFERENCE">Molecular Markers in Cancer - Fifth EORTC-NCI-ASCO, Brussels, Belgium</Source><Source id="1236062" type="CONFERENCE">Drug Design and Medicinal Chemistry - Fifth GTCBio Conference (Part II), San Diego, CA, USA</Source><Source id="1225599" type="CONFERENCE">16th ECCO/36th ESMO Multidisciplinary Cancer Congress (Part I), Stockholm, Sweden</Source><Source id="1223299" type="CONFERENCE">IMPULSE 2011 - 16th EFIS-EJI Symposium, Visegrad, Hungary</Source><Source id="1206608" type="CONFERENCE">Inflammation - Tenth World Conference (Part II), Paris, France</Source><Source id="1202976" type="CONFERENCE">Summary of American Society of Clinical Oncology - 47th Annual Meeting Chicago, IL, USA</Source><Source id="1201009" type="CONFERENCE">Next-Gen Kinase Inhibitors – CHI's Ninth Annual Conference (Part II), Cambridge, MA USA</Source><Source id="1199398" type="CONFERENCE">European Hematology Association - 16th Congress (Part I) – OVERNIGHT REPORT,London, UK</Source><Source id="1192325" type="CONFERENCE">New Technologies in Synthesis and Medicinal Chemistry, Stevenage, UK</Source><Source id="1173545" type="CONFERENCE">Molecular Medicine – CHI's 18th International Tri-Conference (Part IV) -  Mastering Medicinal Chemistry -CHI's Eighth Annual Summit, San Francisco, CA, USA</Source><Source id="1161056" type="CONFERENCE">29th Annual JPMorgan Healthcare Conference (Part III) - OVERNIGHT REPORT, San Francisco, CA, USA</Source><Source id="1157433" type="CONFERENCE">American Society of Hematology (ASH) - 52nd Annual Meeting and Exposition, Orlando, FL, USA</Source><Source id="1150121" type="CONFERENCE">Stem Cells in Drug Discovery and Development - CHI's Inaugural Conference (Part II), San Diego, CA, USA</Source><Source id="1142713" type="CONFERENCE">Therapeutic Antibodies in Europe (Part II), London, UK</Source><Source id="1137332" type="CONFERENCE">Cancer-Induced Bone Disease - Tenth International Conference, Sheffield, UK</Source><Source id="1116947" type="CONFERENCE">Clinical Trials in Cancer - Ninth Annual SMi Conference, London, UK</Source><Source id="1109828" type="CONFERENCE">Summary of American Society of Clinical Oncology - 46th Annual Meeting, Chicago, IL, USA</Source><Source id="1107565" type="CONFERENCE">Cancer Drug Discovery 2010: From Molecules to Medicine, London, UK</Source><Source id="1064938" type="CONFERENCE">Summary of the American Society of Hematology – 51st Annual Meeting &amp;amp; Exposition, New Orleans, LA, USA</Source><Source id="1057832" type="CONFERENCE">Kinase Inhibitors - Third Annual CHI Conference, Boston, MA, USA</Source><Source id="1053262" type="CONFERENCE">Imaging – Informa's Fifth Annual Global Summit (Part I), Berlin, Germany</Source><Source id="1024713" type="CONFERENCE">Gastrointestinal Cancer - 11th World Congress, Barcelona, Spain</Source><Source id="1024416" type="CONFERENCE">2009 Genitourinary Cancers Symposium, Orlando, FL, USA</Source><Source id="1017959" type="CONFERENCE">Summary of the American Society of Clinical Oncology - 45th Annual Meeting, Orlando, FL, USA</Source><Source id="1000762" type="CONFERENCE">Kinase Inhibitor Chemistry - CHI's Inaugural Meeting, Charting the Chemical Space, San Diego, CA, USA</Source><Source id="997900" type="OTHER">Innovative phase I-II study of concomitant and consecutive treatment with Dasatinib and MK-0457 in refractory Ph+ CML and ALL patients </Source><Source id="997517" type="OTHER">Effects of tyrosine kinase inhibitor dasatinib on attachment and migration in PC-3 human prostate cancer cells</Source><Source id="994801" type="OTHER">BMS-754807, a small molecule inhibitor of IGF1R for clinical development</Source><Source id="993368" type="OTHER">Dasatinib and cytarabine (AraC) combinations synergistically inhibit the growth of sarcoma cells</Source><Source id="993367" type="OTHER">In vitro characterization of the antitumor effects of dasatinib (BMS-354825) in combination with paclitaxel and carboplatin in human ovarian cancer cell lines</Source><Source id="992834" type="OTHER">Dasatinib induces autophagy as well as growth arrest in human ovarian cancer cells</Source><Source id="972157" type="OTHER">Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib</Source><Source id="967933" type="OTHER">Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance, Suboptimal Response, or Intolerance to Imatinib (CA180-034)</Source><Source id="967922" type="OTHER">Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium</Source><Source id="967916" type="OTHER">Pregnancy Outcomes among Patients with Chronic Myeloid Leukemia Treated with Dasatinib</Source><Source id="967914" type="OTHER">Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035</Source><Source id="967910" type="OTHER">Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose</Source><Source id="967903" type="OTHER">Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035</Source><Source id="967751" type="OTHER">Dasatinib Has Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL/SLL), a Phase II Trial</Source><Source id="967232" type="OTHER">Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)</Source><Source id="967214" type="OTHER">Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib</Source><Source id="913242" type="OTHER">Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C).</Source><Source id="913110" type="OTHER">Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children's Oncology Group Phase I Consortium.</Source><Source id="912718" type="OTHER">Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML).</Source><Source id="912091" type="OTHER">A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy</Source><Source id="911028" type="OTHER">Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard- dose imatinib: 2-year follow-up data from START-R</Source><Source id="911015" type="OTHER">Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)</Source><Source id="909393" type="OTHER">Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study</Source><Source id="896840" type="OTHER">KXO1 (KX2-391), a Src-family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation in vitro and in vivo</Source><Source id="896457" type="OTHER">CU-0201, a potent, small molecule, multi-targeted inhibitor of HDAC, Abl and Src, effectively inhibits proliferation of both hematological and solid-tumor derived cancer cell lines</Source><Source id="895429" type="OTHER">Src inhibitor Dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling</Source><Source id="894750" type="OTHER">Dasatibib-induced authophagy is synergistically enhanced in combination with temozolomide and is further augmented in PTEN-functional glioma</Source><Source id="894398" type="OTHER">Combined dasatinib and triciribine treatment synergistically inhibits the growth of sarcoma cells</Source><Source id="893501" type="OTHER">The Src family kinase inhibitor, dasatinib, inhibits angiogenesis in vitro and in vivo</Source><Source id="860199" type="OTHER">Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017)</Source><Source id="860196" type="OTHER">Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013)</Source><Source id="860005" type="OTHER">MAPK-Activation in CD34+ CML Stem Cells Induced by Selective Abl-Inhibitors Is Not Observed Using the Combined Src/Abl-Inhibitor Dasatinib</Source><Source id="859893" type="OTHER">Dasatinib Can Be Administered Orally with or without a Meal.</Source><Source id="859890" type="OTHER">Significant Activity of Dasatinib in CLL Demonstrated by Ex-Vivo Assay</Source><Source id="859816" type="OTHER">Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program</Source><Source id="859814" type="OTHER">Dasatinib Inhibits Multiple Myeloma Growth by Blocking PDGF-Rb and c-Src Activity in Patient-Derived Tumor and Endothelial Cells</Source><Source id="859688" type="OTHER">Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005)</Source><Source id="859254" type="OTHER">Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP)</Source><Source id="859226" type="OTHER">Dasatinib as Front-Line Monotherapy for the Induction Treatment of Adult and Elderly Ph+ Acute Lymphoblastic Leukemia (ALL) Patients: Interim Analysis of the GIMEMA Prospective Study LAL1205</Source><Source id="858207" type="OTHER">Importance of Early Intervention with Dasatinib at Cytogenetic Rather Than Hematologic Resistance to Imatinib</Source><Source id="858204" type="OTHER">Dasatinib (SPRYCEL) in Children and Adolescents with Relapsed or Refractory Leukemia: Preliminary Results of the CA180018 Phase I/II Study from the ITCC Consortium</Source><Source id="858196" type="OTHER">Dasatinib Induces Apoptosis in Chronic Lymphocytic Leukemia and Enhances the Activity of Rituximab and Fludarabine</Source><Source id="858159" type="OTHER">Long-Term Efficacy of Dasatinib in Chronic-Phase CML: Results from the Phase I Trial (CA180002)</Source><Source id="857026" type="OTHER">BCR-ABL Kinase Domain Mutations and Their Kinetics on Second Line Dasatinib or Nilotinib Therapy in CML Patients after Imatinib Failure: A Cooperative Evaluation of Four Different Detection Methods</Source><Source id="856958" type="OTHER">Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients</Source><Source id="856502" type="OTHER">A Phase II Study of Dasatinib in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL/SLL)</Source><Source id="856501" type="OTHER">Clonal Large Granular Lymphocyte (LGL) Expansion Associated with Dasatinib Therapy</Source><Source id="856500" type="OTHER">Dasatinib-Induced Platelet Dysfunction</Source><Source id="856499" type="OTHER">Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors</Source><Source id="856498" type="OTHER">Pleural Effusions Associated with Use of Dasatinib in Chronic Myeloid Leukemia May Have an Auto-Immune Pathogenesis</Source><Source id="856497" type="OTHER">Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy</Source><Source id="856496" type="OTHER">Immunoglobulin Prophylaxis in Patients Undergoing Hematopoietic Stem Cell Transplantation  Systematic Review and Meta-Analysis</Source><Source id="856495" type="OTHER">The Src-Abl Kinase Inhibitor Dasatinib (BMS-354825) Shows Anti-Proliferative and Anti-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL) Cells In Vitro</Source><Source id="856494" type="OTHER">Gene Expression Profile Reveals a Unique Pattern of Protein Kinases in Chronic Lymphocytic Leukemia (CLL): Potential Role of the Second Generation Protein Kinase Inhibitors</Source><Source id="856364" type="OTHER">Cost-Effectiveness Analysis in Canada of Dasatinib Versus Imatinib for the Treatment of Chronic Myelogenous Leukemia in Patients with Imatinib Resistance</Source><Source id="856363" type="OTHER">Unlike Imatinib, Dasatinib Uptake into Chronic Myeloid Leukaemia Cells Is Independent of hOCT1 Expression</Source><Source id="856361" type="OTHER">Phase II Study of Dasatinib (SPRYCEL) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis</Source><Source id="856360" type="OTHER">Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFR</Source><Source id="856358" type="OTHER">Response to Dasatinib in Patients with Aggressive Systemic Mastocytosis with D816V Kit Mutation</Source><Source id="856353" type="OTHER">Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015)</Source><Source id="856352" type="OTHER">Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB)</Source><Source id="846081" type="OTHER">Drug datasheet: Sprycel</Source><Source id="820119" type="OTHER">From cytotoxic agents to targeted therapies: A new era in oncology research</Source><Source id="784299" type="OTHER">The dual ABL/SRC inhibitors dasatinib, SKI-606, and INNO-406 are potent inhibitors of T cell acute lymphoblastic leukemia cell lines expressing the NUP214-ABL1 fusion kinase</Source><Source id="783231" type="OTHER">Activity of dasatinib in human osteosarcoma</Source><Source id="783226" type="OTHER">Pulsed ABL kinase inhibition with dasatinib achieves equivalent inhibition of proliferation and induction of apoptosis as continuous ABL kinase inhibition</Source><Source id="783223" type="OTHER">Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival</Source><Source id="783221" type="OTHER">The Src family kinase inhibitor dasatinib (BMS-354825) blocks migration and invasion of human melanoma cells</Source><Source id="783115" type="OTHER">Dasatinib sensitizes chronic lymphocytic leukemia lymphocytes to chemotherapeutic agents</Source><Source id="782488" type="OTHER">Dasatinib blocks the growth, migration, and invasion of breast cancer cells through inhibition of Src family kinases</Source><Source id="782486" type="OTHER">Dasatinib and rapamycin synergistically inhibit the proliferation of cells expressing oncogenic KIT kinase via global inhibition of AKT-dependent signaling</Source><Source id="782169" type="OTHER">Phase I study (CA180021-segment 1) to evaluate the effect of ketoconazole on the pharmacokinetics of dasatinib in patients with advanced solid tumors</Source><Source id="777356" type="OTHER">Dasatinib (BMS-354825) inhibits Src family kinases and downstream STAT5 signaling in chronic myelogenous leukemia cells</Source><Source id="685170" type="OTHER">NCT00345826: Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia</Source><Source id="679682" type="OTHER">NCT00337454: Phase I/II Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All Who Are Resistant to or Intolerant of Treatment in Japan</Source><Source id="671336" type="OTHER">Committee for Orphan Medicinal Products February 2006 Meeting</Source><Source id="642920" type="OTHER">BMY, NVS: New Treatments for CML: Small Opportunity for Dasatinib and AMN107 in Gleevec-Resistant Patients</Source><Source id="642906" type="OTHER">www.clinicaltrials.gov - Studies currently recruiting for BMS compounds</Source><Source id="566677" type="OTHER">Comprehensive protein kinase profiling panels for inhibitor selectivity screening</Source><Source id="524608" type="OTHER">BMS-354825 in treating patients with chronic phase chronic myelogenous leukemia that is resistant to imatinib mesylate</Source><Source id="2164758" type="OTHER">DASCERN 2-YEAR EXTENDED FOLLOW-UP OF DASATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO HAVE SUBOPTIMAL RESPONSES TO 3 MONTHS OF IMATINIB</Source><Source id="2164349" type="OTHER">DASFREE 2-YEAR UPDATE: DASATINIB DISCONTINUATION IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND DEEP MOLECULAR RESPONSE (DMR)</Source><Source id="2133734" type="OTHER">DDR2 inhibition enhances response to anti-PD-1 immunotherapy</Source><Source id="2121711" type="OTHER">Sprycel</Source><Source id="2121709" type="OTHER">Sprycel</Source><Source id="2098882" type="OTHER">Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)</Source><Source id="2098370" type="OTHER">Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial</Source><Source id="2098232" type="OTHER">Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern</Source><Source id="2098197" type="OTHER">Health-Related Quality of Life Outcomes in Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Dasatinib and Low Dose Pegylated Interferon</Source><Source id="2098141" type="OTHER">First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response</Source><Source id="2045756" type="OTHER">SURVIVAL AFTER 1, 3 AND 5 YEARS OF TYROSINE KINASE INHIBITOR THERAPY IN SIMPLICITY, AN OBSERVATIONAL STUDY OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS IN ROUTINE CLINICAL PRACTICE</Source><Source id="2045667" type="OTHER">INTOLERANCES AND HOSPITALIZATIONS AFTER 1, 3 AND 5 YEARS OF TKI THERAPY IN SIMPLICITY, A STUDY OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA PATIENTS IN ROUTINE CLINICAL PRACTICE</Source><Source id="2045249" type="OTHER">EU Prescribing Information: Sprycel</Source><Source id="2044310" type="OTHER">Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer</Source><Source id="2039596" type="OTHER">Final results from a phase II study of 5-fluorouracil, oxaliplatin, and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma.</Source><Source id="2039481" type="OTHER">Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP).</Source><Source id="1988823" type="OTHER">Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice</Source><Source id="1988765" type="OTHER">Treatment Characteristics and Deep Molecular Response in Chronic Phase – Chronic Myeloid Leukemia Patients Treated with Second-Line Nilotinib or Dasatinib: A Multi-Country Retrospective Chart Review Study</Source><Source id="1988654" type="OTHER">Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)</Source><Source id="1988398" type="OTHER">CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)</Source><Source id="1988376" type="OTHER">Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience</Source><Source id="1988343" type="OTHER">Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP)</Source><Source id="1965701" type="OTHER">Characterization of Dasatinib Pharmacokinetics in Support of Dose Recommendation in Pediatric Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase</Source><Source id="1960753" type="OTHER">A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04</Source><Source id="1949086" type="OTHER">Drug website: Spycel HCP</Source><Source id="1949084" type="OTHER">Drug website: Tasigna</Source><Source id="1949079" type="OTHER">What Are the Key Statistics About Chronic Myeloid Leukemia?</Source><Source id="1949068" type="OTHER">Chronic Myeloid Leukemia</Source><Source id="1939461" type="OTHER">5-YEAR EFFICACY OF DASATINIB AND IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DOSE MODIFICATIONS FROM DASISION</Source><Source id="1939381" type="OTHER">ANALYSIS OF DASATINIB AND IMATINIB 5-YEAR EFFICACY AND SAFETY BASED ON BASELINE COMORBIDITY AND AGE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) IN DASISION</Source><Source id="1932414" type="OTHER">A phase I dose expansion cohort study of dasatinib in combination with bevacizumab in advanced solid tumors (NCT01445509).</Source><Source id="1932030" type="OTHER">Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.</Source><Source id="1885408" type="OTHER">Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients</Source><Source id="1881612" type="OTHER">Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial</Source><Source id="1881532" type="OTHER">Dasatinib Exerts Differential Effects on Normal and BCR-ABL Positive Hematopoietic Cells in a Transgenic Mouse Model of Chronic Phase-CML</Source><Source id="1881378" type="OTHER">Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib – the Dasfree Study</Source><Source id="1881312" type="OTHER">Prognostic Value of Clonal Evolution at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors</Source><Source id="1873334" type="OTHER">3Q16 PostView - Raising Sales &amp; EPS Estimates</Source><Source id="1873333" type="OTHER">Bristol-Myers Squibb - Waiting for combo</Source><Source id="1870062" type="OTHER">3Q Model Update: Setting the Base to Deliver Compelling Operating Leverage</Source><Source id="1870060" type="OTHER">Strong Quarter; Upgrading to Long-term Buy</Source><Source id="1870059" type="OTHER">Earnings Growth Drops 21%. Reiterate Neutral.</Source><Source id="1870058" type="OTHER">Bristol-Myers Squibb: BMY: HOLD: Raising EPS Estimates; MYSTIC Keeps Us On The Sidelines</Source><Source id="1870057" type="OTHER">Bristol-Myers Squibb Company:Visibility Into 2017 Earnings, Longer-Term Spending Guidance and Competitor Setback Bode Well for Shares</Source><Source id="1870056" type="OTHER">BMY: 3Q16 Postview - Beats, raises, promises flat spending for 4y (highly unusual for a big growing company)</Source><Source id="1870055" type="OTHER">Margin comfort masks a growth dilemma</Source><Source id="1867889" type="OTHER">Biotechnology - Third-Quarter Earnings Preview and Outlook</Source><Source id="1867887" type="OTHER">Q3:16 Results Preview</Source><Source id="1867849" type="OTHER">Bristol-Myers Squibb: BMY: HOLD: NSCLC Downside And Takeout Scenarios Puts c$39 Floor On BMY</Source><Source id="1867848" type="OTHER">3Q beat/FY16 raise, new cost initiatives</Source><Source id="1867847" type="OTHER">Global Pharmaceuticals: 3Q16 EPS Preview - Model changes and updated perspectives</Source><Source id="1865649" type="OTHER">Global Pharmaceuticals: R&amp;D productivity continues to see upswing - good news for drug investors</Source><Source id="1865645" type="OTHER">Post correction, BMY risks remain to downside</Source><Source id="1833232" type="OTHER">IO &amp; Diabetes Model Updates: Pharma Targets Cut as Competition Intensifies</Source><Source id="1833230" type="OTHER">Disappointing Checkmate-026 Data Likely to Hurt Opdivo Commercially</Source><Source id="1805801" type="OTHER">Abiraterone acetate (AA) followed by randomization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC)</Source><Source id="1805179" type="OTHER">Global Pharmaceuticals: "Monthly Controversies" Report on AZN, BMY, LLY, GSK, MRK, NOVN, PFE, ROG, SAN (October '16)</Source><Source id="1803595" type="OTHER">Pharmaceutical Industry Pulse</Source><Source id="1803590" type="OTHER">Reducing PT to $62 as Opdivo Threats Grow into ESMO</Source><Source id="1797119" type="OTHER">Bristol-Myers Squibb: BMY: HOLD: PT Cut to $57 for Rough Mid Term Ride Ahead; Prefer AZN for IO Exposure</Source><Source id="1795044" type="OTHER">Bristol-Myers Squibb (Sell, TP=$50) - Rating reiterated - Still searching for the bottom - J. Smith (5p)</Source><Source id="1789793" type="OTHER">Bristol-Myers Squibb, Merck: Updated Forecasts Following CheckMate-026 Failure</Source><Source id="1787831" type="OTHER">Downgrade to Neutral (from Buy), PT to $68 (from $86) on Negative CM-26 Results</Source><Source id="1787830" type="OTHER">Bristol-Myers Squibb : Lowering estimates and PT, maintain Hold</Source><Source id="1787829" type="OTHER">BMY's CM-026 Failure Hands Lung Momentum to MRK's Keytruda.</Source><Source id="1787828" type="OTHER">Still Bullish on IO/IO Prospects, but Next 9 Months Will be Rough; PT to $75</Source><Source id="1787827" type="OTHER">Bristol-Myers Squibb Company:Opdivo Failure in Front-Line Non-Small Cell Lung Cancer a Huge Surprise - Downward Revisions But Maintain Outperform Rating</Source><Source id="1787826" type="OTHER">CM-026 Physician Conference Call Wrap-Up; BMY Model Implications</Source><Source id="1785995" type="OTHER">2Q16 Post View: Raising Revenue &amp; EPS on Solid Execution</Source><Source id="1785994" type="OTHER">Low quality sales beat, modest upward to FY16</Source><Source id="1785993" type="OTHER">CheckMate-026 Anxieties Overcome Modest Beat And Raise</Source><Source id="1785992" type="OTHER">OUS Opdivo Sales Trends Impress as US Slows; All Eyes on CM-26; PT $85</Source><Source id="1785991" type="OTHER">Bristol-Myers Squibb : Solid Q</Source><Source id="1785990" type="OTHER">Bristol-Myers Squibb: Full 2Q Postview - Another Beat And Raise, But More Modest This Time Around</Source><Source id="1784226" type="OTHER">Q2:16 Results Preview</Source><Source id="1784206" type="OTHER">Global Pharmaceuticals: 2Q16 EPS Preview - Model Changes and Updated Perspectives</Source><Source id="1784196" type="OTHER">Biotechnology: Second-Quarter Earnings Preview and Outlook</Source><Source id="1782347" type="OTHER">Pharmaceutical Industry Pulse</Source><Source id="1782332" type="OTHER">Bristol-Myers Squibb : Model tweaks and 2Q16 preview, raising PT to $68</Source><Source id="1782331" type="OTHER">ABBV, BMY, JNJ, LLY, MRK - Preview of Earnings for 2Q 2016</Source><Source id="1782328" type="OTHER">U.S. Biopharmaceuticals: 2Q16 Earnings Preview</Source><Source id="1780558" type="OTHER">Global Pharma QM: Q2'16 Earnings Pre-Op Edition</Source><Source id="1780557" type="OTHER">2Q Preview: Continued Strong Rx Trends Suggest Top-Line Beat</Source><Source id="1777691" type="OTHER">Virology Headwinds Begin to Mount. Reiterate Neutral</Source><Source id="1775812" type="OTHER">Global Pharmaceuticals: IPAB News Coming This Week?</Source><Source id="1774789" type="OTHER">New and Generic Drug Approvals</Source><Source id="1772884" type="OTHER">Global Pharmaceuticals: "Monthly Controversies" Report on AZN, BMY, LLY, GSK, MRK, NOVN, PFE, ROG, SAN (June '16)</Source><Source id="1771860" type="OTHER">IO Position Strengthened; Model Updated</Source><Source id="1769864" type="OTHER">Survival outcomes of sustained MR4.5 in patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKI)</Source><Source id="1769526" type="OTHER">A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607)</Source><Source id="1769052" type="OTHER">Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION</Source><Source id="1762284" type="OTHER">Bristol-Myers Squibb: BMY: HOLD: Estimates Bumped, but Better Entry Points May Yet Come</Source><Source id="1759835" type="OTHER">1Q PostView: Raising Estimates &amp; PT to $86 (from $80) on Solid Launch Execution</Source><Source id="1759834" type="OTHER">Bristol-Myers Squibb : Good Q, raising PT to $64</Source><Source id="1759833" type="OTHER">Bristol-Myers Squibb Company:First-Quarter Results and 2016 Outlook Highlight Operating Momentum</Source><Source id="1759832" type="OTHER">Bristol-Myers Squibb: Full 1Q Postview - Solid Beat; Guidance Raised; Lots Of Important IO News Ahead In The Category</Source><Source id="1757427" type="OTHER">1Q Preview: Surprisingly Strong Business Trends Bode Well for Leverage</Source><Source id="1757426" type="OTHER">Oncology Focus Drives Improving Cost Control. Reiterate Neutral.</Source><Source id="1755970" type="OTHER">Global Pharma QM: Q1'16 Earnings Pre-Op Edition</Source><Source id="1754729" type="OTHER">Model Update</Source><Source id="1754728" type="OTHER">Q1 Earnings Preview</Source><Source id="1754727" type="OTHER">Opdivo's Survival Benefit Key Near Term in H&amp;N but Keytruda's Very Competitive</Source><Source id="1754726" type="OTHER">Q1:16 Results Preview</Source><Source id="1754725" type="OTHER">ABBV, BMY, GILD, JNJ, LLY, MRK, SGEN, VRTX - Preview of Earnings for 1Q 2016-And So It Begins</Source><Source id="1754724" type="OTHER">Bristol-Myers Squibb (Sell, TP=$48) - Initiation of coverage - Time to jump out of the bubble - J. Smith (26p)</Source><Source id="1754721" type="OTHER">U.S. Biopharmaceuticals: 1Q16 Earnings Preview</Source><Source id="1744833" type="OTHER">Global Pharmaceuticals: "Monthly Controversies" Report on AZN, BMY, LLY, GSK, MRK, NOVN, PFE, ROG, SAN (Mar '16)</Source><Source id="1742584" type="OTHER">Pharmaceutical Industry Pulse</Source><Source id="1740586" type="OTHER">BMY: 2016 Pharma Top Pick</Source><Source id="1737937" type="OTHER">Is this the end of innovation in biopharma?</Source><Source id="1736421" type="OTHER">Major Pharmaceuticals - Sentiment on Sector Poor, But Fundamentals Remain Strong; 4Q15 Earnings 2nd Opinion</Source><Source id="1736280" type="OTHER">Opdivo launch execution is impressive; renal &amp; head/neck add new legs of growth</Source><Source id="1736279" type="OTHER">Model Implications 0f Increased Opdivo Sales Forecasts</Source><Source id="1734603" type="OTHER">Bristol-Myers Squibb: BMY: HOLD: Solid Q4'15 Results As Opdivo Continues To Gain Momentum, But Threats Loom</Source><Source id="1732840" type="OTHER">The Long View: Global Pharmaceuticals - A Comparative Analysis On New Models To 2025</Source><Source id="1732807" type="OTHER">Bristol-Myers Squibb - Well positioned to deliver in 2016</Source><Source id="1732806" type="OTHER">BMY - BUY - Investment in Cancer Therapy Is Both a Risk and a Reward in 2016</Source><Source id="1732805" type="OTHER">Bristol-Myers Squibb Company : Model Update Following 4Q Results</Source><Source id="1732804" type="OTHER">Q4:15 Results Preview</Source><Source id="1732803" type="OTHER">Bristol-Myers Squibb: Full 4Q Postview - Another Solid Beat, '16 Guidance In-Line, Remains A Best-In-Class LT Grower</Source><Source id="1730917" type="OTHER">Operating Margin Expansion Drives Our Bullish Thesis; PT to $80 from $74</Source><Source id="1730916" type="OTHER">Bristol-Myers Squibb Company:Fourth-Quarter Results and 2016 Outlook Highlight Operating Momentum</Source><Source id="1730915" type="OTHER">ABBV, BMY, JNJ, LLY, VRTX: No Fever Anywhere; First Wave of Earnings Previews for the Week of January 24</Source><Source id="1730914" type="OTHER">Growing Into Its Multiple. Reiterate Neutral</Source><Source id="1730913" type="OTHER">Bristol-Myers Squibb : Tweaking model post Q, maintain Hold and $61 PT</Source><Source id="1730912" type="OTHER">Bristol-Myers Squibb: 4Q15 Earnings Preview</Source><Source id="1729136" type="OTHER">2016 Outlook: Opdivo + Yervoy + Novel IO Combos = Sustained Operating Leverage</Source><Source id="1729135" type="OTHER">Global Pharma QM: Q4'15 Earnings Pre-Op and 2016 Outlook Edition</Source><Source id="1729134" type="OTHER">Bristol-Myers Squibb - Early bird catches the worm; up to Buy</Source><Source id="1727672" type="OTHER">Pharmaceutical Industry Pulse</Source><Source id="1727670" type="OTHER">Global Pharmaceuticals: Outlook in 2016 for AZN, BMY, LLY, GSK, MRK, NOVN, PFE, ROG, SAN ("Monthly Controversies")</Source><Source id="1726017" type="OTHER">2016 Preview: A Year of Two Halves...</Source><Source id="1722717" type="OTHER">Valuation difficult to justify</Source><Source id="1721305" type="OTHER">Best Ideas For 2016: Immune Oncology Driving Estimates Higher</Source><Source id="1718726" type="OTHER">BMY - Upgrading to BUY - Time to Stop Foolin' Around; BMY Is a BUY</Source><Source id="1718468" type="OTHER">A Photosensitizer Verteporfin Has Light-Independent Anti-Leukemic Activity for Ph-Positive Acute Lymphoblastic Leukemia and Synergistically Works with Dasatinib in Vivo</Source><Source id="1718319" type="OTHER">Dasatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Persistent, Low-Grade Nonhematologic Toxicity to Imatinib: Results from Dasperse (CA180-400)</Source><Source id="1716575" type="OTHER">Bristol-Myers Squibb Company:Early Approval of Opdivo in Renal Cell Carcinoma Shows Continued Upside of Drug's Potential</Source><Source id="1715294" type="OTHER">Bristol-Myers Squibb : Tweaking model post Q</Source><Source id="1710968" type="OTHER">Opdivo Beat Drives Price Target Rise to $63</Source><Source id="1710966" type="OTHER">Beat &amp; Raise 3Q Results Driven by Opdivo &amp; HCV, Again</Source><Source id="1710965" type="OTHER">Bristol-Myers Squibb Company:Top-Line Beat Due to Strong Opdivo and Hepatitis C Franchise Sales; Guidance Raised Again</Source><Source id="1710964" type="OTHER">Bristol-Myers Squibb: Full Q3 Postview - Strong Beat, Guidance Raised, Well-Positioned In I/O, But Valuation High</Source><Source id="1708246" type="OTHER">3Q:15 Preview: Business Trends Intact Despite Pricing Fears</Source><Source id="1708198" type="OTHER">Global Pharmaceuticals: 3Q15 EPS Preview - Model Changes and Updated Perspectives</Source><Source id="1708193" type="OTHER">ABBV, BMY, LLY, MRK - 3Q15 Large Cap Pharma Preview</Source><Source id="1706292" type="OTHER">Q3:15 Results Preview</Source><Source id="1706275" type="OTHER">3Q15 Large-Cap Pharma Preview</Source><Source id="1705094" type="OTHER">Global Pharma QM: Q3'15 Earnings Pre-Op Edition</Source><Source id="1702117" type="OTHER">Bristol-Myers Squibb Company:Opdivo Plus Yervoy Approval Marks First Immuno-Oncology Combination Approved by FDA</Source><Source id="1702116" type="OTHER">Merck, Bristol-Myers Squibb: Keytruda Narrow Label, As Expected</Source><Source id="1701007" type="OTHER">PHARMACEUTICAL INDUSTRY PULSE</Source><Source id="1697934" type="OTHER">Global Pharmaceuticals: R&amp;D Productivity Finally Turning the Corner?! Important New Data Suggests It Is</Source><Source id="1694294" type="OTHER">Global Pharmaceuticals: "Monthly Controversies" Report on AZN, BMY, LLY, GSK, MRK, NOVN, PFE, ROG, SAN (Sept '15)</Source><Source id="1694287" type="OTHER">Model Implications From Increased Opdivo Sales Forecasts</Source><Source id="1690071" type="OTHER">Fair Market Value Reached. Upgrading to Neutral.</Source><Source id="1688413" type="OTHER">Model Dusting: ABBV, BMY, GILD, JNJ, LLY, MACK, MRK</Source><Source id="1688412" type="OTHER">Model Update</Source><Source id="1682704" type="OTHER">Bristol 2Q Earnings Beat Low Quality. Reiterate UW.</Source><Source id="1682702" type="OTHER">Post 2Q Model Update Highlighted by Increased Investment, w/ Breakout 2017E</Source><Source id="1682700" type="OTHER">Bristol-Myers Squibb Company : 2Q Takeaways - Opdivo Positioned for Rapid Uptake</Source><Source id="1682699" type="OTHER">Bristol-Myers Squibb: BMY: HOLD: Opdivo, HCV &amp; Eliquis Boost 2015, But Mid-Term Challenges Mount</Source><Source id="1680342" type="OTHER">Model Update</Source><Source id="1680341" type="OTHER">Bristol-Myers Squibb : Tweaking model post Q</Source><Source id="1680340" type="OTHER">Bristol-Myers Squibb: Q2 Preview: How is Opdivo doing?</Source><Source id="1680339" type="OTHER">Bristol-Myers Squibb Company:Strong Second-Quarter Operating Results and Outlook</Source><Source id="1680338" type="OTHER">Bristol-Myers Squibb Company:Early Stoppage of CheckMate-025 Shows First Immuno-Oncology Agent to Demonstrate Benefit in Renal Cell Carcinoma</Source><Source id="1680337" type="OTHER">Bristol-Myers Squibb: Full Q2 Postview - Solid Quarter, But Revised Outlook More Measured Than Investors Wanted</Source><Source id="1680336" type="OTHER">BMY, NOVN, PFE: A First For Opdivo; Bodes Well For I/O, Highlights Risk With More "Traditional" Cancer Drugs</Source><Source id="1679469" type="OTHER">Dasatinib-Associated Pleural Effusion in Patients with Hematologic and Solid Malignancies,</Source><Source id="1678525" type="OTHER">Global Pharma QM: Q2'15 Earnings Pre-Op Edition</Source><Source id="1678513" type="OTHER">Bristol-Myers Squibb Company : Thoughts Heading into Opdivo Launch in 2L Lung Cancer</Source><Source id="1678512" type="OTHER">Pharmaceutical Industry Pulse</Source><Source id="1676891" type="OTHER">Global Pharmaceuticals: "Monthly Controversies" Report on AZN, BMY, LLY, GSK, MRK, NOVN, PFE, ROG, SAN (June '15)</Source><Source id="1671839" type="OTHER">Bristol-Myers Squibb: Highlights From "Pipelines Unplugged" Call #6 With Four Senior R&amp;D Executives</Source><Source id="1671838" type="OTHER">Long-Run Risks in Immuno-Oncology; Initiate Underweight</Source><Source id="1670470" type="OTHER">ATTEMPT TO EARLY DISCONTINUE DASATINIB FIRST LINE IN CHRONIC PHASE CML PATIENTS IN EARLY MOLECULAR RESPONSE AND INCLUDED IN THE PROSPECTIVE OPTIM-DASATINIB TRIAL</Source><Source id="1670468" type="OTHER">INDIVIDUALIZED IMATINIB THERAPY BASED ON [C]MIN LEVELS MONITORING IN NEWLY DIAGNOSED CML PATIENTS RESULTED IN HIGHER MAJOR MOLECULAR RESPONSE RATES AT 12 MONTHS. RESULTS OF THE OPTIM-IMATINIB STUDY</Source><Source id="1669182" type="OTHER">EFFICACY AND SAFETY OF DASATINIB VS. IMATINIB IN LATIN AMERICAN SUBPOPULATION FROM THE DASISION TRIAL IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE (CP)</Source><Source id="1669180" type="OTHER">E1117 EFFICACY AND SAFETY FOR DASATINIB IN EARLY CHRONIC PHASE CML PATIENTS WITH LATE SUBOPTIMAL RESPONSE TO FRONTLINE IMATINIB. PRELIMINARY RESULTS FROM DASAPOST STUDY</Source><Source id="1669172" type="OTHER">ESTIMATED GLOMERULAR FILTRATION RATES OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIS) IN DASATINIB TRIALS: DASISION (CA180-056), CA180-034, AND CA180-035</Source><Source id="1667227" type="OTHER">BMY, MRK, ROG, AZN: Biomarker Data Increasingly Shows Concordance, Changes Landscape</Source><Source id="1664891" type="OTHER">Global Pharmaceuticals: Monthly Review of Controversies w/AZN, BMY, LLY, GSK, MRK, NVS, PFE, ROG, SAN - May '15</Source><Source id="1662542" type="OTHER">Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance)</Source><Source id="1662379" type="OTHER">HER3 and paxillin signaling in ER+ HER2- metastatic breast cancer (MBC) patients receiving letrozole (L) vs letrozole plus dasatinib (L+D) in a randomized phase II trial</Source><Source id="1662020" type="OTHER">Quality of life analysis of NCCTG N0877 (Alliance): Phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM)</Source><Source id="1661559" type="OTHER">NCCTG N0872 (Alliance): A randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM)</Source><Source id="1660657" type="OTHER">Bristol-Myers Squibb - All the eggs in the I-O basket</Source><Source id="1660656" type="OTHER">Estimates Raised, Keyed To Higher Opdivo Forecasts</Source><Source id="1658231" type="OTHER">1Q Highlights: Strong Base Business &amp; Eliquis Set Stage for Opdivo in Lung</Source><Source id="1655992" type="OTHER">Bristol-Myers Squibb: Full Q1 Postview - Solid Story Continues; Probably "Sand-Bagging" on Guidance</Source><Source id="1655991" type="OTHER">Bristol-Myers Squibb : Tweaking model post Q, sticking with Hold</Source><Source id="1655990" type="OTHER">Bristol-Myers Squibb Company:Strong First-Quarter Operating Results and Outlook; Expect High Visibility at ASCO Annual Meeting</Source><Source id="1654188" type="OTHER">Global Pharmaceuticals: 1Q15 EPS Preview - Model Changes and Updated Perspectives</Source><Source id="1654174" type="OTHER">Q1:15 Results Preview</Source><Source id="1654173" type="OTHER">Bristol-Myers Squibb (w/implications for MRK, Roche, AZN): Checkmate-057 Stopped Early, As Most Had Expected</Source><Source id="1652173" type="OTHER">Global Pharma QM: Q1'15 Earnings Pre-Op Edition</Source><Source id="1652170" type="OTHER">First-Quarter Earnings Preview</Source><Source id="1647364" type="OTHER">Global Pharmaceuticals: Monthly Review of Controversies w/AZN, BMY, LLY, GSK, MRK, NVS, PFE, ROG, SAN - Mar '15</Source><Source id="1641552" type="OTHER">Updating Forecast to Reflect Fx and Opdivo; Benefit/ Risk Remains Favorable</Source><Source id="1641551" type="OTHER">AZN, BMY, MRK, NVS: Perspective On Upcoming FDA AdCom On DPP4 Cardiovascular Studies - Implications For TECOS?</Source><Source id="1640846" type="OTHER">Dasatinib Modulates M1/M2 Polarization And Improves Cognitive Deficits In A Mouse Model Of Neuroinflammation</Source><Source id="1639465" type="OTHER">Bristol-Myers Squibb Company : Raising Estimates On Early 2L sq.NSCLC Approval: Reiterate OW</Source><Source id="1639464" type="OTHER">Bristol-Myers Squibb Company:Broader-Label, Earlier-Than-Expected Approval for Opdivo in Lung Cancer an Upside Surprise</Source><Source id="1623107" type="OTHER">Opdivo Approved In Advanced Melanoma; Modest Changes To Model</Source><Source id="1618827" type="OTHER">Global Pharmaceuticals: Monthly Review of Controversies w/AZN, BMY, LLY, GSK, MRK, NVS, PFE, ROG, SAN - Dec '14</Source><Source id="1618691" type="OTHER">Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results</Source><Source id="1618598" type="OTHER">Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study</Source><Source id="1618186" type="OTHER">Dasatinib Plus Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323</Source><Source id="1617933" type="OTHER">Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)</Source><Source id="1617536" type="OTHER">Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)</Source><Source id="1609951" type="OTHER">Bristol-Myers Squibb Company : Shares Remain Well Positioned After Last Week’s Opdivo Rally; Raising Estimates</Source><Source id="1609950" type="OTHER">Lung Docs' Feedback on -063 Bolsters Confidence in Raised Opdivo Estimates</Source><Source id="1607616" type="OTHER">Solid Quarter; Increasing PT to $36</Source><Source id="1607615" type="OTHER">Halloween Treat: Raising Our DCF PT to $66 on Higher Opdivo/PD1 Ests</Source><Source id="1607614" type="OTHER">Bristol-Myers Squibb : Sticking with Hold ahead of key data readouts</Source><Source id="1607613" type="OTHER">Bristol-Myers Squibb Company : Updating Model Post 3Q Results</Source><Source id="1607612" type="OTHER">Bristol-Myers Squibb Company:CheckMate-063 Results Highlight Opdivo Activity and Durability in Area of Unmet Need</Source><Source id="1607611" type="OTHER">Bristol-Myers Squibb: 063 Data Decent (As One Would Expect With A PD1) And Reassure That The "Bear Case" Is Null</Source><Source id="1605298" type="OTHER">CHECKMATE-063 Preview: Benchmarking 3rd Line Squamous NSCLC Therapies</Source><Source id="1605297" type="OTHER">Bristol-Myers Squibb: CHECKMATE for lung cancer?</Source><Source id="1603317" type="OTHER">Global Pharmaceuticals: 3Q14 EPS Preview - Model Changes and Updated Perspectives</Source><Source id="1603275" type="OTHER">Major Pharma : Adjusting Models for Recent FX Changes; Establishing 2015 Price Targets</Source><Source id="1603274" type="OTHER">Global Pharma QM: Q3'14 Earnings Pre-op Edition</Source><Source id="1601487" type="OTHER">Sunvepra Hep C Application Withdrawn in the U.S.; Reiterate Sell</Source><Source id="1600041" type="OTHER">Pharmaceutical Industry Pulse</Source><Source id="1599674" type="OTHER">Global Pharmaceuticals: Drug Pipeline Review - September 2014 (64 New Updates)</Source><Source id="1596265" type="OTHER">Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumors: A multicenter two stage phase II trial SAKK 56/07</Source><Source id="1593546" type="OTHER">Bristol-Myers Squibb : Initiating at Hold</Source><Source id="1591870" type="OTHER">Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis</Source><Source id="1584233" type="OTHER">Bristol-Myers Squibb Company : Takeaways from Recent Mgmt Meetings; Reiterate OW into a Number of Important 2H/14 and 2015 Catalysts</Source><Source id="1584232" type="OTHER">2Q14 Post View &amp; Model Update - IO Leadership Intact</Source><Source id="1584231" type="OTHER">Only Modest Changes To Model Post Q2 Results</Source><Source id="1582217" type="OTHER">Opdivo and Hep C Programs Progressing Rapidly; Increasing PT to $34</Source><Source id="1582216" type="OTHER">Bristol-Myers Squibb Company : Updating Model Following 2Q Results</Source><Source id="1582215" type="OTHER">Impressive 2Q Eliquis Growth Carries BMY Toward IO Catalysts</Source><Source id="1582214" type="OTHER">Bristol-Myers Squibb: 2Q14 Earnings: Slow and steady</Source><Source id="1582213" type="OTHER">Bristol-Myers Squibb: Full Q2 Postview - EPS Beat on Higher "Other Inc"; Making Progress On Various Pipeline Programs</Source><Source id="1581750" type="OTHER">Bristol-Myers Squibb Company:Second-Quarter Results Showcase Pipeline Progress; Expect Active Second-Half News Calendar</Source><Source id="1580297" type="OTHER">Bristol-Myers Squibb Company : Updating Model</Source><Source id="1578883" type="OTHER">Pharmaceutical Industry Pulse</Source><Source id="1578506" type="OTHER">Global Pharmaceuticals: 2Q14 EPS Preview - Model Changes and Updated Perspectives</Source><Source id="1578477" type="OTHER">Global Pharma QM: Earnings Pre-Op (July) Edition</Source><Source id="1576926" type="OTHER">Despite Tempered IO Outlook for BMY, Risk/Reward Remains Attractive</Source><Source id="1576334" type="OTHER">PHASE 2 DOUBLE-BLIND, PLACEBO–CONTROLLED TRIAL OF DASATINIB ADDED TO GEMCITABINE FOR SUBJECTS WITH LOCALLY-ADVANCED PANCREATIC CANCER (LAPC)</Source><Source id="1575003" type="OTHER">Odds Of Nivolumab Phase III Lung Trial Success - Ahead Of The Curve Series</Source><Source id="1573449" type="OTHER">Bullish Meeting w/ Management Highlights Leadership in "Huge" IO Market</Source><Source id="1572456" type="OTHER">Global Pharmaceuticals: Monthly Review of Controversies w/AZN, BMY, LLY, GSK, MRK, NVS, PFE, ROG, SAN - June'14</Source><Source id="1570119" type="OTHER">SAFETY AND TOLERABILITY OF DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL): POOLED ANALYSIS OF OVER 2400 PATIENTS</Source><Source id="1570041" type="OTHER">DASATINIB DAILY DOSE OPTIMIZATION BASED ON RESIDUAL DRUG LEVELS RESULTED IN REDUCED RISK OF PLEURAL EFFUSIONS AND HIGH MOLECULAR RESPONSE RATES: FINAL RESULTS OF THE RANDOMIZED OPTIM DASATINIB TRIAL</Source><Source id="1569372" type="OTHER">Bristol-Myers Squibb: Highlights from “Pipelines Unplugged” Conference Call #9 with Various R&amp;D Executives</Source><Source id="1567070" type="OTHER">SAFETY AND TOLERABILITY OF DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL): POOLED ANALYSIS OF OVER 2400 PATIENTS</Source><Source id="1566743" type="OTHER">ASCO 2014 Follow-up: Positives &amp; Negatives for IO's Pioneer</Source><Source id="1566742" type="OTHER">Bristol-Myers Squibb: Highlights from BMY Analyst Meeting at ASCO</Source><Source id="1562690" type="OTHER">Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC)</Source><Source id="1558508" type="OTHER">Global Pharmaceuticals: ASCO Abstracts - High-Level Thoughts &amp; Summary Of Detailed Data Across US/EU Pharma</Source><Source id="1558003" type="OTHER">Therapeutic Effect Of Dasatinib On Lung Morphofunction And Inflammation In Experimental Pulmonary And Extrapulmonary Acute Respiratory Distress Syndrome</Source><Source id="1557992" type="OTHER">Endothelial Toxicity Of The Cancer Therapeutic Agent Dasatinib</Source><Source id="1557859" type="OTHER">Dasatinib Inhibits Neutrophil Degranulation In Response To Sterile And Non-Sterile Stimuli Without Impairing Bacterial Killing </Source><Source id="1557732" type="OTHER"> Therapy With Src Tyrosine Kinase Inhibitor Reduced Lung Inflammation And Fibrogenesis In Experimental Silicosis</Source><Source id="1552728" type="OTHER">Nivolumab Launch Likely a 2015 Event; Still too Much Value Dependent on One Drug</Source><Source id="1552727" type="OTHER">Tweaking our Model to Reflect OpEx &amp; 6-Month Delay of Nivo Launch</Source><Source id="1552726" type="OTHER">From Here to ASCO: What Moves the Needle for BMY</Source><Source id="1552725" type="OTHER">Bristol-Myers Squibb Company : Updating Model Post 1Q/14 Results</Source><Source id="1552724" type="OTHER">Bristol-Myers Squibb Company:First-Quarter Results Showcase Pipeline Progress; Financial Guidance Updated</Source><Source id="1552723" type="OTHER">Bristol-Myers Squibb: Full Q1 Postview - EPS Beat, But Focus Mostly On Slight Slippage With Nivolumab (PD-1) Filing</Source><Source id="1548279" type="OTHER">Biotechnology: Thoughts on the Biotech Sector Pullback and First Quarter 2014 Earnings Cycle Preview</Source><Source id="1548266" type="OTHER">Global Pharma QM: Q1'14 Edition; Downgrade JNJ (Hold), Upgrade LLY (Hold)</Source><Source id="1540707" type="OTHER">Global Pharmaceuticals: New Medical Journal Article Has Relevance to Potential Heart Failure Signal Seen with DPP4s</Source><Source id="1540696" type="OTHER">Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse model </Source><Source id="1535171" type="OTHER">Global Pharmaceuticals: Monthly Review of Controversies w/AZN, BMY, LLY, GSK, MRK, NVS, PFE, ROG, SAN - Mar'14</Source><Source id="1533725" type="OTHER">Pharmaceutical Industry Pulse</Source><Source id="1533565" type="OTHER">Pharmaceutical industry pulse</Source><Source id="1532842" type="OTHER">Updating Forecasts to Better Reflect HCV Oppt'y &amp; More IO Tumors</Source><Source id="1528917" type="OTHER">TFDA website: Sprycel film-coated tablets</Source><Source id="1520390" type="OTHER">4Q13 Postview - NIVO is the Focus</Source><Source id="1518416" type="OTHER">Global Pharmaceuticals: 4Q13 EPS Preview - Model Changes and Updated Perspectives</Source><Source id="1516659" type="OTHER">Pharmaceutical Industry Pulse</Source><Source id="1515923" type="OTHER">2014 Global Pharma QM: Raising JNJ (Buy), AZN (Hold); Lowering NOVN (Hold)</Source><Source id="1504458" type="OTHER">Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium</Source><Source id="1504305" type="OTHER">Pharmacokinetic (PK) and Pharmacodynamic  (PD) Study Of Dasatinib In Chronic Phase Of Newly Diagnosed Chronic Myeloid Leukemia (CML-CP)</Source><Source id="1504293" type="OTHER">Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial</Source><Source id="1503763" type="OTHER">Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response</Source><Source id="1503124" type="OTHER">NK-Cells In Dasatinib-Treated Chronic Myeloid Leukemia Patients Display a Unique Phenotype Associated With Cytotoxic Potential</Source><Source id="1503115" type="OTHER">Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials</Source><Source id="1503110" type="OTHER">Clinical Efficacy and Safety Of Dasatinib For Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase In Japan</Source><Source id="1502532" type="OTHER">Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac</Source><Source id="1501609" type="OTHER">Cyprus approval and launch information</Source><Source id="1467730" type="OTHER">Sprycel</Source><Source id="1466334" type="OTHER">Slovak Republic launch information</Source><Source id="1464050" type="OTHER">Sprycel</Source><Source id="1459845" type="OTHER">SPRYCEL 20 mg film-coated tablets</Source><Source id="1459805" type="OTHER">Prezista</Source><Source id="1458965" type="OTHER">Sprycel</Source><Source id="1452075" type="OTHER">Sprycel</Source><Source id="1450511" type="OTHER">Iceland Launch Information</Source><Source id="1449097" type="OTHER">SPRYCEL</Source><Source id="1444818" type="OTHER">Czech Republic Launch Information</Source><Source id="1438015" type="OTHER">Greece Launch Information</Source><Source id="1436575" type="OTHER">Sprycel film-coated table</Source><Source id="1436572" type="OTHER">Sprycel film-coated table</Source><Source id="1433806" type="OTHER">Effects of dasatinib on prostate cancer bone metastases and normal bone measured by 18F-fluoride PET: Preliminary results from ACRIN 6687</Source><Source id="1427012" type="OTHER">Correlation of 18F-fluoride PET response to dasatinib in castration-resistant prostate cancer bone metastases with progression-free survival: Preliminary results from ACRIN 6687</Source><Source id="1426867" type="OTHER">Sprycel</Source><Source id="1399982" type="OTHER">Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors (NCT01445509)</Source><Source id="1383820" type="OTHER">Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial</Source><Source id="1368868" type="OTHER">Sprycel + Comprimido revestido por película</Source><Source id="1363325" type="OTHER">Phase II trial of dasatinib in combination with weekly paclitaxel for patients with metastatic breast carcinoma</Source><Source id="1356794" type="OTHER">dasatinib</Source><Source id="1350836" type="OTHER">Iclusig Prescribing Information</Source><Source id="1345271" type="OTHER">SPRYCEL 20 mg film-coated tablets</Source><Source id="1325906" type="OTHER">DASATINIB FIRST-LINE TREATMENT IN GASTROINTESTINAL STROMAL TUMORS. A MULTICENTER PHASE II TRIAL OF THE SAKK (SAKK 56/07)</Source><Source id="1320465" type="OTHER">Higjlights of Prescribing Information: BOSULIF</Source><Source id="1304833" type="OTHER">FIRST-LINE DASATINIB PLUS CONVENTIONAL CHEMOTHERAPY IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: THE KOREAN PROSPECTIVE PHASE II STUDY</Source><Source id="1304490" type="OTHER">DASATINIB PLUS FLUDARABINE IN PATIENTS WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A MULTICENTER PHASE II STUDY</Source><Source id="1304467" type="OTHER">Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis</Source><Source id="1304417" type="OTHER">EFFICACY AND SAFETY OF DASATINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): EUROPEAN SUBPOPULATION ANALYSIS OF THE PHASE 3 DASISION TRIAL</Source><Source id="1302580" type="OTHER">SIX-YEAR FOLLOW-UP OF PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING DASATINIB</Source><Source id="1302128" type="OTHER">DASATINIB MAY OVERCOME THE NEGATIVE PROGNOSTIC IMPACT OF KIR2DS1 IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA</Source><Source id="1296551" type="OTHER">Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib</Source><Source id="1296547" type="OTHER">Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up</Source><Source id="1296466" type="OTHER">Adherence and persistence to second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia</Source><Source id="1296444" type="OTHER">Effect of inhibition of Src and insulin/insulin-like growth factor-1 receptor (IR/IGF-1R) on tumor activity and bone turnover in prostate cancer (PCa) models in vivo relative to inhibition of either kinase alone</Source><Source id="1285272" type="OTHER">Ocular Safety of Dasatinib in a Rabbit Model</Source><Source id="1279565" type="OTHER">Dasatinib inhibits experimental PVR progression</Source><Source id="1270139" type="OTHER">CONTRIBUTION OF ABCC4 (MRP4)-MEDIATED GASTRIC ABSORPTION TO THE ORAL BIOAVAILABILITY OF DASATINIB</Source><Source id="1261378" type="OTHER">Inhibition of Src and insulin/insulin-like growth factor-1 receptor (IR/IGF-1R) on tumors and bone turnover in prostate cancer (PCa) models in vivo compared with inhibition of either kinase alone</Source><Source id="1246044" type="OTHER">Results of a Phase II Trial Of Dasatinib As Frontline Therapy For Chronic Myeloid Leukemia (CML) in Chronic Phase</Source><Source id="1246024" type="OTHER">Dasatinib Has a Dual Mode of Action: Direct BCR-ABL1 Mediated Anti-Leukemic Effects Are Complemented by Promotion of Th1-Type and NK-Cell Mediated Cellular Immune Responses</Source><Source id="1245215" type="OTHER">The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy</Source><Source id="1245214" type="OTHER">Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38- Stem Cell Level: Results From Randomized NordCML006 Study</Source><Source id="1244160" type="OTHER">Impact of Dose Reductions and Interruptions Due to Adverse Events (AEs)on Efficacy in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Receiving Either Dasatinib (D) or Imatinib(IM): Analysis of the DASISION Trial</Source><Source id="1244156" type="OTHER">Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed CML-CP: Analysis of Molecular Response Kinetics in the DASISION Trial</Source><Source id="1244123" type="OTHER">Rapid and Sustained Increase of LGL and Rare CMV-Reactivation During Dasatinib Treatments in CML</Source><Source id="1243864" type="OTHER">Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease – Results of the DASA-CBF Trial From the French AML Intergroup</Source><Source id="1243622" type="OTHER">Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB)</Source><Source id="1242866" type="OTHER">Phase II Pilot Study of Oral Dasatinib in Subjects with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed Conventional Therapy</Source><Source id="1242845" type="OTHER">Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)</Source><Source id="1242842" type="OTHER">Clonal Dasatinib Large Granular Expansion Is Associated with Suboptimal and Optimal  Leukemia Net Response Criteria in Chronic Myelogenous Leukemia</Source><Source id="1242647" type="OTHER">Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180-211)</Source><Source id="1242270" type="OTHER">First-Line Dasatinib Plus Conventional Chemotherapy in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Interim Analysis of the Korean Prospective Phase II Study</Source><Source id="1242267" type="OTHER">Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)</Source><Source id="1240559" type="OTHER">Phase I trial of dasatinib and ixabepilone in patients with solid tumors</Source><Source id="1240075" type="OTHER">Src inhibitor Dasatinib reduces the metastatic phenotype of breast cancer cells</Source><Source id="1198262" type="OTHER">EFFICACY AND SAFETY OF DASATINIB COMPARED WITH IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): MINIMUM 24-MONTH FOLLOW-UP FROM THE DASISION TRIAL</Source><Source id="1198002" type="OTHER">LONG-TERM EFFICACY AND SAFETY OF DASATINIB 100 MG ONCE-DAILY (QD) IN PATIENTS WITH IMATINIB-RESISTANT/INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CML-CP): 5-YEAR FOLLOW-UP FROM CA180-034</Source><Source id="1197284" type="OTHER">PLEURAL EFFUSION IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) WHO RECEIVED FIRST-LINE DASATINIB IN THE DASISION TRIAL: PATIENT CHARACTERISTICS, MANAGEMENT, AND OUTCOMES</Source><Source id="1196659" type="OTHER">A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST)</Source><Source id="1196107" type="OTHER">Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib</Source><Source id="1196106" type="OTHER">Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION</Source><Source id="1152419" type="OTHER">Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up</Source><Source id="1152388" type="OTHER">Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial</Source><Source id="1151727" type="OTHER">Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared with Those with No or Only One BCR-ABL Mutation</Source><Source id="1151725" type="OTHER">Dasatinib (Versus Imatinib) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Analysis of Safety and Efficacy by Use of Baseline Medications in the DASISION Trial</Source><Source id="1151714" type="OTHER">Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial</Source><Source id="1151705" type="OTHER">Occurrence and Management of Pleural Effusion and Outcomes In Patients during Dasatinib Treatment for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) In the First-Line Setting: Analysis of the DASISION Trial</Source><Source id="1151700" type="OTHER">Dasatinib In Children and Adolescents with Relapsed or Refractory Leukemia: Results of the CA180018 Phase 1 Dose-Escalation Study of the Innovative Therapies for Children with Cancer (ITCC) Consortium</Source><Source id="1150379" type="OTHER">Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib</Source><Source id="1150343" type="OTHER">The Heatshockprotein-90 Inhibitor IPI-504 Potently Overcomes Tyrosinekinase Inhibitor-Induced Activation of Cell Protection Mechanisms and Degrades HSP-Client Proteins KIT and FLT3 In Acute Leukemia and Mastocytosis Models</Source><Source id="1150061" type="OTHER">In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34 Progenitors Is Not Significantly Different Than That Observed In CD34 Mature Cells</Source><Source id="1143122" type="OTHER">UPDATE 1-Bristol-Myers cancer drug receives new approval</Source><Source id="1105068" type="OTHER">A phase I/II trial of DTIC and dasatinib in metastatic melanoma</Source><Source id="1105027" type="OTHER">Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer</Source><Source id="1104786" type="OTHER">Phase II study of dasatinib in advanced non-small cell lung cancer</Source><Source id="1104675" type="OTHER">A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607)</Source><Source id="1104621" type="OTHER">CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM)</Source><Source id="1104032" type="OTHER">Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML)</Source><Source id="1104025" type="OTHER">Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily</Source><Source id="1103622" type="OTHER">Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study</Source><Source id="1103621" type="OTHER">Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph+) leukemias resistant or intolerant to imatinib</Source><Source id="1103344" type="OTHER">Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study</Source><Source id="1103145" type="OTHER">Three parallel randomized phase II trials of dasatinib plus hormone therapy (HT) in advanced ER+ breast cancer (ER+ ABC)</Source><Source id="1090091" type="OTHER">Akt inhibitor MK-2206 combined with Dasatinib synergistically inhibits the growth of sarcoma cells</Source><Source id="1059964" type="OTHER">Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)</Source><Source id="1059935" type="OTHER">Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB)</Source><Source id="1059478" type="OTHER">Predictors of Long-Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP)</Source><Source id="1059471" type="OTHER">Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure</Source><Source id="1059243" type="OTHER">Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation</Source><Source id="1059240" type="OTHER">Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged &gt; 60 Years Resistant/Intolerant to Imatinib</Source><Source id="1058284" type="OTHER">Activity of SYK and PLCγ2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib</Source><Source id="1058250" type="OTHER">Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)</Source><Source id="1058240" type="OTHER">Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP)</Source><Source id="1058239" type="OTHER">Opportunistic Infections Are Uncommon with Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)</Source><Source id="1058237" type="OTHER">Weekend Drug Holiday of Dasatinib in CML Patients Not Tolerating Standard Dosing Regimens. Reducing Toxicity with Maintained Disease Control</Source><Source id="1058234" type="OTHER">Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group</Source><Source id="1058230" type="OTHER">Prevalence of Large Granular Lymphocyte Proliferation in Chronic Myeloid Leukemia (CML) Patients Treated with Dasatinib</Source><Source id="1034310" type="OTHER">Phase II study of dasatinib in non-small cell lung cancer (NSCLC)</Source><Source id="1013007" type="OTHER">A phase II study of once-daily dasatinib for patients with castration resistant prostate cancer (CRPC) (CA180085)</Source><Source id="1009718" type="OTHER">Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma</Source><Source id="1009702" type="OTHER">Dasatinib and docetaxel combination treatment for patients with castration- resistant progressive prostate cancer: A phase I/II study (CA180086)</Source><Source id="1009619" type="OTHER">A phase II trial of dasatinib in advanced melanoma</Source><Source id="1009557" type="OTHER">Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004</Source><Source id="1009554" type="OTHER">Dasatinib in advanced HER-2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088</Source><Source id="1009521" type="OTHER">Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph+ CML and ALL patients</Source><Source id="1009149" type="OTHER">Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS)</Source><Source id="1007214" type="OTHER">Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC)</Source><Source id="869457" type="TRIAL">Trial of Dasatinib (Sprycel®) in Subjects With Hormone-Refractory Prostate Cancer (NCT00570700)</Source><Source id="861013" type="TRIAL">NCT00481247: A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML</Source><Source id="846825" type="TRIAL">NCT00538980: Dastinib in Polycythemia Vera</Source><Source id="802203" type="TRIAL">NCT00339144: Study of BMS-354825 in Patients With Solid Tumors</Source><Source id="802201" type="TRIAL">NCT00371254: A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-Negative' Breast Cancer</Source><Source id="790334" type="TRIAL">NCT00439270: Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer</Source><Source id="782618" type="TRIAL">NCT00429949: A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma</Source><Source id="769527" type="TRIAL">NCT00410813: Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone</Source><Source id="690351" type="TRIAL">NCT00371345: Phase II Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+)Breast Cancer</Source><Source id="690333" type="TRIAL">NCT00371254: Phase II Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-Negative' Breast Cancer</Source><Source id="683850" type="TRIAL">NCT00339144: Study of BMS-354825 in Patients With Solid Tumors</Source><Source id="2154270" type="TRIAL">NCT01238211: Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</Source><Source id="2154220" type="TRIAL">NCT01445509: Dasatinib in combination with bevacizumab to treat advanced solid tumors</Source><Source id="2117130" type="TRIAL">[NCT01593254]: Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)</Source><Source id="2108892" type="TRIAL">[NCT01725204]:Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia (NordCML007)</Source><Source id="2094080" type="TRIAL">NCT00869401: Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</Source><Source id="2069346" type="TRIAL">NCT00696072: Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic</Source><Source id="2069197" type="TRIAL">NCT01306942: Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients</Source><Source id="2069101" type="TRIAL">NCT00452673: Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer</Source><Source id="2068643" type="TRIAL">NCT00566618: Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis</Source><Source id="2068640" type="TRIAL">NCT01471106: Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer</Source><Source id="2068637" type="TRIAL">NCT00546104: Phase II Dasatinib Study in Advanced Breast Cancer</Source><Source id="2068636" type="TRIAL">NCT00924352: Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer</Source><Source id="2068372" type="TRIAL">NCT00444015: Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)</Source><Source id="1981398" type="TRIAL">NCT00306202:Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia</Source><Source id="1929721" type="TRIAL">NCT00777036: A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib</Source><Source id="1874630" type="TRIAL">NCT02954523: Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations</Source><Source id="1759748" type="TRIAL">NCT02750514: A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)</Source><Source id="1706330" type="TRIAL">NCT01357655: Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)</Source><Source id="1668644" type="TRIAL">NCT00892177: Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme</Source><Source id="1664912" type="TRIAL">NCT01482728: A Phase 0 Pharmacodynamic Study of Dasatinib in Women With Newly Diagnosed Endometrial Cancer</Source><Source id="1660001" type="TRIAL">NCT02428855 ; Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma</Source><Source id="1644002" type="TRIAL">[NCT02389972] Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study</Source><Source id="1515902" type="TRIAL">NCT02011945: A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia</Source><Source id="1443431" type="TRIAL">[NCT01514864]: Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation</Source><Source id="1439219" type="TRIAL">NCT00671788: Dasatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer</Source><Source id="1437698" type="TRIAL">EudraCT 2006-003581-34: Dasatinib Compassionate Use</Source><Source id="1436006" type="TRIAL">UMIN000008999: Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission</Source><Source id="1432776" type="TRIAL">ACTRN12607000609459: Dasatinib plus Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</Source><Source id="1418279" type="TRIAL">EudraCT 2006-006555-12: Phase II, Multicenter, Open-evaluating Dasatinib in Patients with Acute Myelogenous Leukemia (AML) with Core Binding Factors (CBF) Resistant to Conventional Chemotherapy or Molecular Relapse</Source><Source id="1414929" type="TRIAL">JapicCTI-100987: The continuous administration test for acute lymphocytic leukemia and Philadelphia chromosome-positive chronic myeloid leukemia of BMS-354825</Source><Source id="1408862" type="TRIAL">UMIN000007944: Stop Imatinib or Dasatinib Study in CP-CML Patients Mainitaining Complete Molecular Response for Two Years</Source><Source id="1408817" type="TRIAL">UMIN000007413: Phase II Study of Safety and Efficacy. Dasatinib in Patients with Chronic Phase Chronic Myelogenous Leukemia achieving a Major Molecular Response on Imatinib</Source><Source id="1406887" type="TRIAL">JapicCTI-090840: Phase I trial of BMS-354825 that target solid cancer patients</Source><Source id="1406886" type="TRIAL">JapicCTI-090839: The clinical phase 2 study for BCR-ABL-positive chronic phase chronic myeloid leukemia or Philadelphia chromosome-positive of BMS-354825</Source><Source id="1406885" type="TRIAL">JapicCTI-090838: Unblinded to compare targeting Philadelphia chromosome-positive newly diagnosed chronic phase chronic myeloid leukemia patients, dasatinib and (BMS-354825) of imatinib standard dose (400 mg), randomized, multi-center second Phase III trial</Source><Source id="1406884" type="TRIAL">JapicCTI-090837: The clinical phase 1/2 trial for acute lymphocytic leukemia and Philadelphia chromosome-positive chronic myeloid leukemia of BMS-354825</Source><Source id="1403230" type="TRIAL">UMIN000002779: Phase II clinial trial of Dasatinib for Imatinib resistant or refractory chronic myeloid leukemia in chronic phase</Source><Source id="1393654" type="TRIAL">EudraCT 2008-006854-17: A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATINGTHE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)</Source><Source id="1353339" type="TRIAL">RBR-36w269: A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer</Source><Source id="1353069" type="TRIAL">NCT00560391: Dasatinib in Combination With Revlimid (and Dexamethasone)</Source><Source id="1353058" type="TRIAL">NCT00560352: Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma</Source><Source id="1326194" type="TRIAL">NCT00624585: Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts</Source><Source id="1287434" type="TRIAL">NCT00852566: Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia (NordCML006)</Source><Source id="1216296" type="TRIAL">NCT01395017: Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)</Source><Source id="1194726" type="TRIAL">NCT00103844: Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia</Source><Source id="1175136" type="TRIAL">NCT00903006: Trial of Fulvestrant, MK-0646, and Dasatinib for metastatic hormone receptor-positive HER2-negative breast cancer</Source><Source id="1162103" type="TRIAL">NCT00464620: Trial of Dasatinib in Advanced Sarcomas</Source><Source id="1161611" type="TRIAL">NCT00538980: Dasatinib in Polycythemia Vera</Source><Source id="1159950" type="TRIAL">NCT01218477: Dasatinib Combo With SMO Inhibitor (BMS-833923)</Source><Source id="1127806" type="TRIAL">NCT00764309: Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis</Source><Source id="1106413" type="TRIAL">NCT00123474: Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML</Source><Source id="1034277" type="TRIAL">NCT00564876: Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer (TOP0706)</Source><Source id="1016169" type="TRIAL">NCT00597038: A Phase I/II Study of Dasatinib and Dacarbazine</Source><Source id="996385" type="CORPORATE">Novartis AG: Form 20-F for the year ended 31 December 2008</Source><Source id="996069" type="CORPORATE">Bristol-Myers Squibb: Annual Report for the year ended 31 December 2008</Source><Source id="990277" type="CORPORATE">Bristol-Myers Squibb: In the pipeline</Source><Source id="979588" type="CORPORATE">Bristol-Myers Squibb Company F4Q08 and Full Year Earnings Call Transcript</Source><Source id="962315" type="CORPORATE">Bristol-Myers Squibb Co. Q3 2008 Earnings Conference Call Transcript</Source><Source id="959032" type="CORPORATE">Bristol-Myers Squibb: In the pipeline</Source><Source id="898386" type="CORPORATE">Hope for tomorrow: our pipeline today (selected compounds under investigation)</Source><Source id="891485" type="CORPORATE">Annual Report 2007 - Bristol-Myers Squibb Co</Source><Source id="857971" type="CORPORATE">Bristol-Myers Squibb Investor Meeting (December 5, 2007)</Source><Source id="801347" type="CORPORATE">Form 10-K 2006: Bristol Myers</Source><Source id="800896" type="CORPORATE">Bristol-Myers Squibb 2006 Annual Report</Source><Source id="677521" type="CORPORATE">Drug development pipeline: dasatinib</Source><Source id="671658" type="CORPORATE">Sanford C Bernstein &amp;amp; Co Strategic Decisions Conference: Presentation by Peter R Dolan, CEO, Bristol-Myers Squibb</Source><Source id="642108" type="CORPORATE">Bristol-Myers Squibb - 2005 Investment Community Meeting, December 12, 2005</Source><Source id="605691" type="CORPORATE">Bristol-Myers Squibb presentation at Sanford C Bernstein &amp;amp; Co Strategic Decisions Conference</Source><Source id="591298" type="CORPORATE">Form 10K - Bristol-Myers Squibb - For the fiscal year ended December 31, 2004</Source><Source id="573635" type="CORPORATE">Drug development update: BMS-354825</Source><Source id="572379" type="CORPORATE">Publications: Leukemia insights newsletter</Source><Source id="572056" type="CORPORATE">Bristol-Myers Squibb R and D Review, November 17, 2004</Source><Source id="2139934" type="CORPORATE">Approved determinations and designations for prescription medicines: Orphan drug designation for dasatinib for the treatment of paediatric patients with chronic myeloid leukaemia</Source><Source id="2123173" type="CORPORATE">Form 10-K 2018 - Bristol-Myers Squibb Co</Source><Source id="2117890" type="CORPORATE">Pipeline as of January 31 2018</Source><Source id="2088094" type="CORPORATE">In the Pipeline: October 22, 2018</Source><Source id="2066973" type="CORPORATE">[Bristol-Myers Squibb Co]: pipeline</Source><Source id="2028443" type="CORPORATE">Bristol-Myers Squibb; Pipeline, as of April 01, 2018</Source><Source id="2005764" type="CORPORATE">Form 10-K 2017 - Bristol-Myers Squibb Co</Source><Source id="2002774" type="CORPORATE">Bristol-Myers Squibb; Pipeline, as of January 01, 2018</Source><Source id="2002770" type="CORPORATE">4th Quarter 2017 Earnings Review &amp;amp; Investor Update</Source><Source id="1997107" type="CORPORATE">Bristol-Myers Squibb; Pipeline, as of October 13, 2017</Source><Source id="1935115" type="CORPORATE">Bristol-Myers Squibb ASCO 2017</Source><Source id="1922036" type="CORPORATE">In the Pipeline: April 01, 2016</Source><Source id="1902314" type="CORPORATE">Form 10-K 2016 - Bristol-Myers Squibb Co</Source><Source id="1896983" type="CORPORATE">Pipeline as of January 01, 2017</Source><Source id="1865852" type="CORPORATE">Annual Report 2015. For the year ending December 31, 2015</Source><Source id="1807184" type="CORPORATE">In the Pipeline - As of October 1, 2016</Source><Source id="1767495" type="CORPORATE">In the Pipeline: May 01, 2016</Source><Source id="1765054" type="CORPORATE">Consolidated Financial Results FY2016 Q1</Source><Source id="1744012" type="CORPORATE">Pharmaceutical Benefits Scheme: Dasatinib</Source><Source id="1740028" type="CORPORATE">In the Pipeline: January 01, 2016</Source><Source id="1735637" type="CORPORATE">Form 10-K 2015 - Bristol-Myers Squibb Co</Source><Source id="1713583" type="CORPORATE">Otsuka Holdings Co Ltd - Pipeline Information (as of September 30, 2015)</Source><Source id="1692098" type="CORPORATE">Bristol-Myers Squibb Co website and pipeline (as of June 30, 2015)</Source><Source id="1685349" type="CORPORATE">Consolidated Financial Results FY2015 Q2 (Six Months Ended June 30, 2015)</Source><Source id="1685340" type="CORPORATE">FACT BOOK</Source><Source id="1684963" type="CORPORATE">Otsuka Holdings Co Ltd - Pipeline Information (as of Jun 30, 2015)</Source><Source id="1677083" type="CORPORATE">Bristol-Myers Squibb pipeline (As of December 31, 2014)</Source><Source id="1659664" type="CORPORATE">Otsuka Pharmaceutical Co Ltd - Company Website (as of March 31, 2015)</Source><Source id="1641439" type="CORPORATE">Form 10-K 2014 - Bristol-Myers Squibb Co</Source><Source id="1612582" type="CORPORATE">Otsuka Holdings Co Ltd - Pipeline information</Source><Source id="1596951" type="CORPORATE">Bristol-Myers Squibb website (As of July 10, 2014)</Source><Source id="1584441" type="CORPORATE">Otsuka Pharmaceutical website and pipeline</Source><Source id="1570428" type="CORPORATE">Otsuka Pharmaceutical Company website and Pipeline</Source><Source id="1543464" type="CORPORATE">Bristol-Myers Squibb Co: In the Pipeline (as of February 01, 2014)</Source><Source id="1538244" type="CORPORATE">Bristol-Myers Squibb pipeline</Source><Source id="1528586" type="CORPORATE">Form 10-K 2013 - Bristol-Myers Squibb Co</Source><Source id="1524591" type="CORPORATE">Otsuka Pharmaceutical pipeline</Source><Source id="1515648" type="CORPORATE">BMS: JP Morgan Healthcare Conference</Source><Source id="1512697" type="CORPORATE">Bristol-Myers Squibb Form 10-Q</Source><Source id="1500021" type="CORPORATE">Financial Results Presentation FY2013 Q2 (six months ending September 30, 2013)</Source><Source id="1497790" type="CORPORATE">Bristol-Myers Squibb: Pipeline as of June 30, 2013</Source><Source id="1489744" type="CORPORATE">Bristol-Myers Squibb: Pipeline as of October 01, 2013</Source><Source id="1477516" type="CORPORATE">Bristol-Myers Squibb: Pipeline as of August 01, 2013</Source><Source id="1463375" type="CORPORATE">Financial Results Presentation FY2013 Q1 (Three Months Ending June 30, 2013)</Source><Source id="1420747" type="CORPORATE">Financial Results Presentation FY2012 (Fiscal Year Ending March 31, 2013)</Source><Source id="1399468" type="CORPORATE">Annual Report 2012 - Bristol-Myers Squibb Co</Source><Source id="1392809" type="CORPORATE">Form 10-K 2012 - Bristol-Myers Squibb Co</Source><Source id="1389197" type="CORPORATE">Bristol-Myers Squibb; In the pipeline (as of February 15, 2013)</Source><Source id="1383612" type="CORPORATE">Financial Results Presentation Q3 FY2012 (Nine Months Ending December 30, 2012)</Source><Source id="1368576" type="CORPORATE">Bristol-Myers Squibb; In the pipeline (as of December 31, 2012); Necitumumab removed as of January 29, 2013</Source><Source id="1355929" type="CORPORATE">Bristol-Myers Squibb; In the pipeline (as of December 31, 2012)</Source><Source id="1341067" type="CORPORATE">Bristol-Myers Squibb (Japan): New drug development information (Japanese pipeline as of November 2012)</Source><Source id="1340044" type="CORPORATE">Financial Results Presentation Q2 FY2012 (Six Months Ending September 30, 2012)</Source><Source id="1333971" type="CORPORATE">Bristol-Myers Squibb; In the pipeline (as of June 30, 2012; updated in August 2012 for INX-189 and Amylin compounds)</Source><Source id="1314475" type="CORPORATE">Financial Results Presentation Q1 FY2012 (Three Months Ending June 30, 2012)</Source><Source id="1313404" type="CORPORATE">Bristol-Myers Squibb; In the pipeline (as of June 30, 2012)</Source><Source id="1289911" type="CORPORATE">Financial Results Presentation FY2011 (Fiscal Year Ending March 31, 2012)</Source><Source id="1273838" type="CORPORATE">Bristol-Myers Squibb: 2011 Annual Report</Source><Source id="1264186" type="CORPORATE">Form 10-K: Bristol-Myers Squibb Company (for the fiscal year ended December 31, 2011)</Source><Source id="1261923" type="CORPORATE">Financial Results Presentation Q3 FY2011 (Nine Months Ending December 31, 2011)</Source><Source id="1258009" type="CORPORATE">In the pipeline (as of December 31, 2011)</Source><Source id="1252163" type="CORPORATE">Bristol-Myers Squibb (Japan): Drug development information (as of January 2012)</Source><Source id="1250055" type="CORPORATE">In the pipeline (as of June 30, 2011)</Source><Source id="1242619" type="CORPORATE">Bristol-Myers Squibb (Japan): Drug development information (as of November 2011)</Source><Source id="1238570" type="CORPORATE">Financial Results Presentation Q2 FY2011 (Six Months Ending September 30, 2011)</Source><Source id="1234184" type="CORPORATE">Bristol-Myers Squibb (Japan): Drug development information (as of September 2011)</Source><Source id="1199752" type="CORPORATE">Sprycel (dasatinib): Prescibing information</Source><Source id="1194955" type="CORPORATE">CLINICAL TRIAL RESULTS DASATINIB. Final Clinical Study Report for Study CA180088</Source><Source id="1178388" type="CORPORATE">Annual Report 2010 - Bristol-Myers Squibb Co</Source><Source id="1172766" type="CORPORATE">Bristol-Myers Squibb: In the pipeline (as of December 31, 2010)</Source><Source id="1170676" type="CORPORATE">Bristol-Myers Squibb Co: Form 10-K for the year ended 31 December 2010</Source><Source id="1137023" type="CORPORATE">Paragraph IV Patent Certifications</Source><Source id="1125663" type="CORPORATE">Drug datasheet: Tasigna</Source><Source id="1120772" type="CORPORATE">Bristol-Myers Squibb: In the pipeline (as of June 30, 2010)</Source><Source id="1118830" type="CORPORATE">Bristol-Myers Squibb Q2 2010 Earnings Call Transcript</Source><Source id="1091518" type="CORPORATE">Bristol-Myers Squibb: In the pipeline (as of March 3, 2010)</Source><Source id="1085337" type="CORPORATE">Annual Report 2009 - Bristol-Myers Squibb Co</Source><Source id="1079593" type="CORPORATE">Bristol-Myers Squibb Co: Form 10-K for the year ended 31 December 2009</Source><Source id="1075247" type="CORPORATE">Bristol-Myers Squibb: In the pipeline (as of December 31, 2009)</Source><Source id="1047918" type="CORPORATE">Bristol-Myers Squibb: In the pipeline</Source><Source id="1031896" type="CORPORATE">Bristol-Myers Squibb: In the pipeline</Source></Sources></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugSourcesOutput>